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ABSTRACT OF THE DISSERTATION
UV-INDUCED MELANOMA MOUSE MODEL DEPENDENT ON ENDOTHELIN 3
OVER-EXPRESSION
by
Ana Paula da Silva Benaduce
Florida International University, 2014
Miami, Florida
Professor Lidia Kos, Major Professor
Melanoma is one of the most aggressive types of cancer. It originates
from the transformation of melanocytes present in the epidermal/dermal junction
of the human skin. It is commonly accepted that melanomagenesis is influenced
by the interaction of environmental factors, genetic factors, as well as tumor-host
interactions. DNA photoproducts induced by UV radiation are, in normal cells,
repaired by the nucleotide excision repair (NER) pathway. The prominent role of
NER in cancer resistance is well exemplified by patients with Xeroderma
Pigmentosum (XP). This disease results from mutations in the components of the
NER pathway, such as XPA and XPC proteins. In humans, NER pathway
disruption leads to the development of skin cancers, including melanoma. Similar
to humans afflicted with XP, Xpa and Xpc deficient mice show high sensibility to
UV light, leading to skin cancer development, except melanoma. The Endothelin
3 (Edn3) signaling pathway is essential for proliferation, survival and migration of
melanocyte precursor cells. Excessive production of Edn3 leads to the
accumulation of large numbers of melanocytes in the mouse skin, where they are

viii

not normally found. In humans, Edn3 signaling pathway has also been implicated
in melanoma progression and its metastatic potential. The goal of this study was
the development of the first UV-induced melanoma mouse model dependent on
the over-expression of Edn3 in the skin. The UV-induced melanoma mouse
model reported here is distinguishable from all previous published models by two
features: melanocytes are not transformed a priori and melanomagenesis arises
only upon neonatal UV exposure. In this model, melanomagenesis depends on
the presence of Edn3 in the skin. Disruption of the NER pathway due to the lack
of Xpa or Xpc proteins was not essential for melanomagenesis; however, it
enhanced melanoma penetrance and decreased melanoma latency after one
single neonatal erythemal UV dose. Exposure to a second dose of UV at six
weeks of age did not change time of appearance or penetrance of melanomas in
this mouse model. Thus, a combination of neonatal UV exposure with excessive
Edn3 in the tumor microenvironment is sufficient for melanomagenesis in mice;
furthermore, NER deficiency exacerbates this process.
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INTRODUCTION
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I. INTRODUCTION
Cells in an organism are regulated by several external and internal
pathways leading to the maintenance of homeostasis. Disruption in pathways
related with cell cycle and cell differentiation trigger unrestrained cell proliferation
and abnormal differentiation which, consequently, lead to cancer. As a result,
transformed cells, lose their original finality, invade and disturb adjacent tissues,
forming new tumors called metastases. Skin cancer is a very common type of
cancer (American Cancer Society, 2014a). The different types of skin cancer are
associated to their cells of origin: aberrant melanocytes give rise to malignant
melanoma (MM), while aberrant keratinocytes give rise to non-melanoma skin
cancer (NMSC), which is divided into basal cell carcinoma (BCC) and squamous
cell carcinoma (SCC). Sunlight exposure is the most important environmental risk
factor of skin cancer development. Ultraviolet (UV) rays can directly and indirectly
damage DNA and cause immunosuppression (de Gruijl et al., 2001; Welsh et al.,
2008). In normal human cells, depending on the type of DNA damage, different
types of repair pathways are activated. When excessive DNA damage that
cannot be repaired occurs, the apoptotic pathway is activated causing cells to
undergo programmed cell death. Genetic factors also contribute to UV-mediated
skin cancer development. Individuals who have defects in the pathways
mentioned above and/or are immunosuppressive are greatly more susceptible to
skin cancers. In this chapter, an overview of epidemiological and genetic links of
UV radiation and skin carcinogenesis are described. Skin cancer diagnoses,
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available treatments for the most aggressive type of skin cancer and mouse
models are also reviewed.
1.1 Skin Cancers
Skin cancer, or cutaneous carcinogenesis, is the most frequent form of
cancer diagnosed in white populations and it is, by far, the most common of all
types of cancer (American Cancer Society, 2014b; Diepgen and Mahler, 2002;
Rogers et al., 2010). Skin cancers are mainly divided into three types: Basal Cell
Carcinoma (BCC), Squamous Cell Carcinoma (SCC) and Cutaneous Melanoma.
BCC and SCC are referred together as non-melanoma skin cancer (NMSC)
whereas the cutaneous melanoma is referred as malignant melanoma (MM) or
just melanoma. The occurrence of NMSC is 20 times higher than melanoma;
however melanoma is responsible for most of the skin cancer mortalities
(American Cancer Society, 2014b; Diepgen and Mahler, 2002).
Non-melanoma skin cancer and melanoma are derived from different
types of cells: NMSC arises from transformed epidermal keratinocytes, while
melanoma arises from transformed melanocytes. Melanocytes produce melanin,
a pigment that helps to protect the genetic material in the epidermis basal cells
against light-induced damage. Therefore, melanocytes decrease the lethality of
NMSC (Markovic et al., 2007). Melanocytes are uniformly dispersed in the basal
layer of the epidermis in human skin. They correspond between 1-2% of the cell
population, whereas, keratinocytes represent about 95% of the total cells present
in human epidermis (Figure 1) (Holbrook et al., 1989; Yaar and Gilchrest, 2001).

3

Reporting of NMSCs to the cancer registries is not a requirement, making
it challenging to precisely estimate their occurrence. An analysis of the incidence
of NMSCs in the United States population estimated that over 3.5 million cases
were diagnosed and more than 2.2 million individuals were treated for the
disease in 2006 (Rogers et al., 2010).

Basal cell carcinoma constitutes

approximately 80% of the NMSCs and is characterized by slow growth and
infrequent metastasis, whereas SCC comprises the remaining 20%, shows quick
growth and, when neglected, can metastasize (American Cancer Society,
2014c). The major part of all NMSC cases is highly curable, especially if
diagnosed in early stages (American Cancer Society, 2014a).
Melanoma is the most aggressive of the three main types of skin cancer
and, this aggressiveness is attributed to its high capacity to metastasize. For the
last 30 years, melanoma incidence rates have been increasing. In 1935, the
lifetime risk of developing melanoma was 1 in 1500. Currently, the risk is 1 in 59
(Rigel, 2010). Melanoma incidence increases with age and shows an altered
pattern between women and men (Rigel, 2010). In 2014, in the United States, it
is estimated that 76,100 new cases of melanoma will be diagnosed and that
9,710 patients will die from the disease (American Cancer Society, 2014a).
Metastatic melanoma presents an unpredictable biological behavior, frequently
metastasizing in brain, bones, liver, lungs and viscera (Tas, 2012). Melanoma
metastasis is characterized by rapid dissemination making its treatment very
challenging. The 5-year survival rate for patients with metastatic melanoma is
only 16% (American Cancer Society, 2014a). Most recurrences occur in the
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period of the first three years, and rare cases have been described of over 30
years of latency (Geisler et al., 2013).
1.2 Ultraviolet Radiation
Solar UV radiation has a broad spectrum: low-energy UVA band
(wavelengths of 320 to 400 nm, visible light of 400 to 700 nm), high-energy UVB
band (280 to 320 nm) and UVC band (below 280 nm). The UVC band is totally
absorbed by the ozone layer. Most of the UVB rays are absorbed while passing
through the ozone layer; however the UVA rays are almost not affected.
Therefore, 5 to 10% of UVB and 90 to 95% of UVA arrives at the earth’s surface
level and are capable of reaching human skin (Figure 1) (Daya-Grosjean and
Sarasin, 2005). While UVB is filtered by window glass, UVA is not affected by it.
It is estimated that 50 % of UVA exposure happens in the shade (Schaefer et al.,
1998).
Earth’s radiation depends on the solar altitude which varies according to
the geographic location, time of the day and season (Holzle and Honigsmann,
2005). It is important to point out that with the depletion of the ozone layer, higher
amounts of UV rays, mainly UVB, are reaching the Earth’ surface (McKenzie et
al., 2011; United Nations Environment Programme et al., 2012).
Compared to UVB rays, UVA rays possess the longest wavelengths and
thus penetrate deeper into the skin. As such, UVA rays have a higher chance of
reaching the basal layers where melanocytes and dividing stem cells are located
(Halliday and Cadet, 2012) (Figure 1). The UVB rays penetrate superficially into
the skin and have higher absorption rate by DNA than UVA, as well as being
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considered more mutagenic and cytotoxic than UVA (Cadet et al., 1997; Jhappan
et al., 2003). Additionally, a UVA dose has to be 1000 times stronger than that of
UVB to produce the same level of erythema (Parrish et al., 1982).
Ultraviolet radiation is responsible for several different chronic and acute
effects

on

the

skin.

Chronic

responses

include

photoaging

and

photocarcinogenesis, both caused by cumulative damaged effects of UVA
(mostly formation of reactive oxygen species) and UVB (formation of pyrimidine
dimers) radiation in the cells. The acute responses are very diverse and include
erythema, DNA photodamage, apoptosis, immunosuppression, synthesis of
vitamin D and increased pigmentation (Burke, 2010; Fisher et al., 2002; Ichihashi
et al., 2003; Mason and Reichrath, 2013; Min et al., 2014; Ullrich, 2002;
Yamaguchi et al., 2008).
1.3 Role of UV Radiation in Skin Cancer
In the human body the primary and largest target for UV radiation is the
skin. The ozone layer filters UV waves before it reaches the earth’s surface.
Since the early seventies, concerns about ozone layer depletion have gained
considerable attention and different studies have tried to predict its detrimental
effects on skin cancer incidence (Kelfkens et al., 1990) as well as other impacts
on the earth. As a result of the depletion of the ozone layer, the filtration of UV
rays is less efficient and, the human skin is exposed to a higher amount of UV
rays (Lemus-Deschamps and Makin, 2012; Norval et al., 2011; United Nations
Environment Programme et al., 2012). As a consequence of the high intensities
of UV radiation that humans experience, more damage is being caused to the
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cells in a shorter period of time than it did before (Lemus-Deschamps and Makin,
2012).
The incidence of NMSC and melanoma are mainly related to the
interaction of environmental factors (such as UV light) and genetic factors (such
as skin type, gender, inherited disorders) (Agbai et al., 2014; Barrett et al., 2014;
Goldstein and Tucker, 2001; Pennello et al., 2000; Tamura et al., 2014; Vogel et
al., 2014). Ultraviolet radiation has an important influence in skin cancer
development in two ways: directly, by causing DNA damage (mutations in cellular
DNA) in skin cells and, indirectly, by suppressing the anti-tumor immune
response, which promotes cancer development and facilitates metastasis (Figure
2) (Bald et al., 2014; Chacon-Salinas et al., 2014; Del Bino et al., 2013; Ichihashi
et al., 2003; Katiyar and Mukhtar, 2001; Meeran et al., 2008; Russo et al., 2008;
Welsh et al., 2008). For these reasons, UV is considered the major etiological
factor of skin cancer (Daya-Grosjean and Sarasin, 2005).
People living in world areas with elevated annual sunlight average or
increased erythemogenic UV rays show higher risks of skin cancers, especially
SCC followed by BCC and then melanoma (Armstrong and Kricker, 2001).
Recent studies showed that the incidence of SCC and BCC, in outdoor workers,
increases with proximity to the equator (Bauer et al., 2011; Schmitt et al., 2011).
Chronic, cumulative lifetime UV exposure is the major risk factor for SCC,
whereas intermittent UV exposure is considered to be primarily important in the
pathogenesis of BCC (Armstrong and Kricker, 2001; Rosso et al., 1996).
Melanoma development is related to intense, intermittent solar UV radiation
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exposure and blistering sunburns in childhood and adolescence leading to
cumulative DNA damage in skin cells (Armstrong and Kricker, 2001; Kauffmann
et al., 2008; Rigel, 2010; Whiteman et al., 2001). Skin cancer risk is associated
with the amount of UV radiation exposure and the skin pigmentation level
(Figure 3) (Armstrong and Kricker, 2001; Del Bino et al., 2013; Diepgen and
Mahler, 2002; Rosso et al., 1996).
Individuals with fair skin and red hair (pigmentation phenotype I of
Fitzpatrick scale), characterized by high pheomelanin (red/yellow pigment) to
eumelanin (black/brown pigment) ratio, have the tendency to burn easily rather
than tan and are associated with higher risks of developing skin cancer than
other pigmentation types (Diepgen and Mahler, 2002; Fitzpatrick et al., 1977;
Pathak et al., 1980; Rigel, 2010). Genetically, inactivating polymorphisms of the
melanocortin 1 receptor (MC1R) 1 gene are, in particular, correlated with this
phenotype (Valverde et al., 1995). The melanocyte stimulating hormone (MSH)
and its antagonistic agouti protein are MC1R ligands on melanocytes. Increased
MC1R activity by MSH stimulates the production of eumelanin, whereas minimal
receptor activity either by the binding of the agouti protein or by MC1R
inactivating polymorphisms, leads to the production of pheomelanin pigment
(Lu et al., 1994; Valverde et al., 1995). Population studies of MC1R variant
alleles have shown strong genetic associations between red hair/ fair skin
phenotypes and an increased risk of all forms of skin cancer (Sturm, 2002). This

1

Formatting of gene and protein nomenclature according to The Jackson
Laboratory, 2014 and Wain et al., 2002.
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link is believed to be associated with the fact that pheomelanin has weak
shielding capacity against UV radiation in comparison to eumelanin and also that
pheomelanin has a high potential to generate free radicals upon UV radiation and
was shown that its presence increases the sensibility to UVA-induced DNA
damage (D'Orazio et al., 2006; Ranadive et al., 1986; Wenczl et al., 1998).
Furthermore, recent data suggest that pheomelanin is carcinogenic for
melanoma development via oxidative damage even independently of UV
radiation (Mitra et al., 2012).
1.4 Role of UV Radiation in DNA Damage and DNA Repair
The DNA photodamage is one of the major acute effects caused by UV
radiation. Ultraviolet radiation can cause molecular DNA rearrangements directly
by formation of base dimers and indirectly by oxidative base damage (de Gruijl et
al., 2001). Damaged DNA can in turn lead to the generation of defective proteins,
which can disrupt signaling pathways and, later on, result in skin cancer. Luckily,
most of the DNA damage is efficiently and accurately repaired in normal cells.
Ultraviolet radiation A and UVB, by different mechanisms, can cause DNA
damage and so both are considered to have important roles in skin
carcinogenesis. The UVB rays that reach earth’ surface can easily be absorbed
by DNA bases, mainly by the pyrimidine bases, such as cytosine (C) and thymine
(T), leading to the formation of pyrimidine dimers. It can also be absorbed by
some proteins that have aromatic amino acids, such as tyrosine and tryptophane
(Young, 1997). As a consequence, UVB photon absorption leads to chemical
reactions that can alter DNA structure and composition (de Gruijl et al., 2001).
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The UVA effects, on the other hand, are mainly mediated by the formation of
radicals; therefore, it causes indirect damage to DNA (Kullavanijaya and Lim,
2005). Recently, UVA was also shown to lead to pyrimidine dimers lesions on
DNA by direct absorption (Jiang et al., 2009; Mouret et al., 2006; Mouret et al.,
2010).
Non-DNA endogenous photosensitizers such as melanin, quinone, flavins
and porphyrins, absorb UVA rays and by photochemical interaction produce
reactive oxygen species including hydrogen peroxide, hydroxyl radical,
peroxynitrite and singlet oxygen (Cadet and Douki, 2011; Cadet et al., 2009).
Reactive oxygen species are extremely unstable and reactive molecules that can
lead to DNA strand breaks, oxidation of nucleic acids and cause damage to
cellular proteins (Peak and Peak, 1991; Wenczl et al., 1997). Guanine (G) is the
main oxidized DNA base upon UVA irradiation. Guanine oxidation gives rise to 8oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) (Cadet et al., 2009), which causes
transversion G:C to T:A mutations. This happens because the 8-oxodG is paired
with adenine (A) instead of cytosine (C) during replication (Shibutani et al., 1991).
The DNA oxidized bases are removed either by the nucleotide excision
repair (NER) or by the base excision repair (BER) pathways. The NER pathway
plays a secondary role repairing this type of damage while BER plays a crucial
role. The BER pathway is divided into two subpathways: short-patch BER
(excision of one nucleotide) and long patch BER (excision of two or more
nucleotides) (Matsumoto et al., 1999; Pascucci et al., 1999). The first step of the
BER pathway is the action of a DNA glycosylase. This enzyme removes the

10

oxidized DNA base leaving a non-instructive apurinic/apyrimidinic (AP) site. The
remaining sugar fragments are removed by AP endonucleases. The repair is
finalized by the action of DNA polymerase β, δ or ε and DNA ligase (Matsumoto
et al., 1999; Pascucci et al., 1999).
The most common photoproduct of UV radiation exposure is pyrimidine
dimers (Brash and Haseltine, 1982). Ultraviolet rays, especially shortwave such
as UVB, are absorbed by two neighboring pyrimidine bases in the DNA, leading
to the formation of di-pyrimidine sites resulting in either 6-4 photoproduct (6-4PP:
thymine-cytosine dimers) (Varghese and Patrick, 1969) or cyclobutane
pyrimidine dimer (CPD: thymine dimers, cytosine dimers) (Setlow and Carrier,
1964). Interestingly, after 60 minutes of sun exposure at noon in Kobe, Japan,
during the summer, approximately 100,000 CPD molecules per cell are produced
in human epidermis (reviewed by(Ichihashi et al., 2003). Formation of pyrimidine
dimers disrupts the double strand DNA helix (Park et al., 2002). This bulky lesion
in the DNA is recognized and repaired by the NER pathway (Rastogi et al., 2010;
Setlow and Carrier, 1964). It has been reported that the excision of 6-4 PP is
faster than CPD (Rastogi et al., 2010).
Nucleotide excision repair malfunction is one important step for UV
radiation to cause skin cancer development (Pfeifer and Besaratinia, 2012;
Yarosh et al., 2005). For instance, Xeroderma Pigmentosum (XP) is a rare
autosomal recessive disease characterized by a deficient NER system. As a
result, the photoproducts induced by UV radiation are not repaired, resulting in a
malignant phenotype (Cleaver et al., 2009; Stary and Sarasin, 2002). Xeroderma
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Pigmentosum patients are extremely sensitive to sun exposure and, compared
with unaffected individuals under 20 years of age, they have a 1,000-fold
elevated risk of UV-induced skin cancers, including cutaneous melanoma
(Kraemer et al., 1994).
Nucleotide excision repair has two distinct subpathways: the transcriptioncoupled repair pathway (TCR) which rapidly repairs DNA regions that are
transcriptionally active, and the global genome repair pathway (GGR) which
works less quickly than TCR pathway but repairs both transcriptionally active and
inactive regions (Hoeijmakers, 2001). Both subpathways are a multi-step process
where at least 25 proteins are involved, including the seven XP complementation
group of proteins (XPA, XPB, XPC, XPD, XPE, XPF, and XPG) (Wood et al.,
2005; Wood et al., 2001). Briefly, the NER pathway recognizes DNA
photoproducts via distinct protein complexes, depending on whether the TCR or
the GGR pathway is used. After DNA damage recognition, the transcription factor
IIH (TFIIH) together with two DNA helicases, XPB and XPD, unwind the double
stranded DNA, creating single-stranded DNA. Two endonucleases, the ERCC1XPF complex and XPG, make respective incisions 5’ and 3’ at the sides of the
lesion releasing a 25-27 nucleotide fragment containing the photoproduct
(Friedberg, 2001; Hoeijmakers, 2001). As in the BER pathway, DNA polymerase
and DNA ligase complete the repair.
Ultraviolet radiation can lead to genomic mutations, which threaten the
genomic integrity of the cell and can contribute to tumorigenic processes.
Mutation in critical genes that encode for proteins related to cell cycle control,
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DNA repair or apoptosis, affecting the function of these important proteins, are
strongly connected with early stages of skin cancer (Ortonne, 2002; Pfeifer and
Besaratinia, 2012).
1.5 Role of UV Radiation in Immunosuppression and Skin Cancer
More than 30 years ago Fisher and Kriple (1977) demonstrated that
inoculating UV-irradiated mice with lymphoid cells from another UV-exposed
mice made the recipients unable to reject tumor transplantation, whereas UVirradiate mice inoculated with lymphoid cells from non-UV-irradiated mice
became resistant to tumor grow (Fisher and Kripke, 1977). Their main conclusion
was that UV radiation exposure could affect the immune system and prevent host
anti-tumor response (Fisher and Kripke, 1977).
Ultraviolet-induced immunosuppression is strongly linked with the
development of melanoma and NMSC (Chapman et al. 1995). The suppression
of the immune system by UV radiation assists skin cancer development and
progression, enabling an easier dispersion of cancer cells throughout the body.
The ability of tumor cells to escape immune system detection is called tumor
immune escape (Pardoll, 2003).
Immune system responses can be divided into two main categories:
innate, which act rapidly and has a non-specific response; and, adaptive, which
takes more time because of the response specificity to each antigen and, in
many cases, the antigen is picked up and processed by antigen-presenting cells,
such as langerhans cells, macrophages and dendritic cells. Afterwards, antigen

13

portions are recognized by T-lymphocytes, which then are triggered to proliferate
and produce immune cytokines (Sirisinha, 2014).
Ultraviolet radiation has multiple negative effects in the immune system
and, since early years, it was found to be capable to suppress adaptive immune
responses (Kripke, 1974). Some of these effects include: (1) suppression of the
amount and functionality of antigen-presenting cells (Hill et al., 1999; Nghiem et
al., 2002); (2) induction of the release of immunosuppressive cytokinesis (Bald et
al., 2014; Nghiem et al., 2002); and, (3) induction of T-lymphocytes into
apoptosis (Hill et al., 1999; Ozawa et al., 1996).
Ultraviolet radiation is capable of downregulating already established
immune responses (Damian et al., 1998; Narbutt et al., 2005; Wang et al., 2008).
Increasing amounts of UVB radiation exposure was shown to have a direct
relationship with increasing levels of immune suppression (Matthews et al.,
2010a; Noonan and De Fabo, 1990). On the other hand, UVA exposure displays
a bell-shaped dose response for immune suppression (Matthews et al., 2010b).
The cellular and molecular mechanisms through which UVA and UVB
radiation affect the immune system depends on the amount of exposure. Upon
sub-inflammatory doses of UVB radiation, regulatory B-lymphocytes are
activated (Byrne et al., 2005; Byrne and Halliday, 2005), whereas regulatory Tlymphocytes generally require inflammatory doses (Gorman et al., 2007). Low
doses of UVA exposure has been shown to trigger the alternative complement
pathway inducing systemic immunosuppression (Stapelberg et al., 2009), while
greater doses of UVA was associated to immune protection due to the activation
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of heme oxygenase (enzyme related to oxidative stress protection) (Reeve and
Tyrrell, 1999) and interferon γ (immune system cytokine) (Reeve et al., 1999).
Also, UVA and UVB radiation exposure were shown to have interaction effects
that are far superior than the addition of their effects individually (Poon et al.,
2005).
Skin of newborn children is immunologically immature. There has been
speculations that immune responses from early life stage could determine
melanoma outcomes later in life (Muller et al., 2008). Exposure of neonatal
mouse skin to UV radiation induces a poor inflammatory response compared to
adult skin response, which has an acute inflammatory response within minutes,
thus limiting the development of immunity and promoting a tolerogenic
environment (Muller et al., 2008). Additionally, UV-exposed neonatal mouse skin
revealed microenvironment modifications that can lead to the generation of
antigen-specific regulatory T-lymphocytes, which persists for life. Thus, these
early modulating events may be relevant for the UV-induced melanomagenesis
during adulthood (Muller et al., 2008).
Induced immunosuppression therapy, common in organ transplant
patients, significantly increases skin cancer risk (Feuerstein and Geller, 2008;
Garg et al., 2009; Jemec and Holm, 2003; Tessari and Girolomoni, 2012; Ulrich
et al., 2004). These individuals develop skin cancer more often and typically a
more aggressive form with quicker metastases than normal individuals with a
non-suppressed immune system (Jemec and Holm, 2003). Moreover, skin
cancer rates decrease when the immune suppressive therapy is decreased
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(Jemec and Holm, 2003). Interestingly, while the ratio of SCC:BCC in nontransplanted population is 1:4, this ratio in transplanted population is 4:1, the
complete inversion (Tessari and Girolomoni, 2012).
1.6 Skin Cancer Diagnoses
Macroscopically, a useful clinical evaluation for pigmented lesions is the
so-called ABCDE rule - Asymmetry, Border irregularity, Color variation,
Diameters greater than 6mm and Elevation (Rigel et al., 2005). There is no
similar detection rule for NMSC (Soyer et al., 2012)
It is well established that melanoma tumor thickness is the greatest
prognostic indicator; superficial tumors can be easily cured with a simple surgery,
whereas mortality is closely correlated with increasing in tumor depth (Rigel and
Carucci, 2000; Sahin et al., 1997). Besides the depth measurement of
melanoma, other histological prognostic factors include ulceration (absence of an
intact epidermal layer overlying the melanoma), mitotic rate (an indicator of tumor
proliferation in the dermis) and lymphatic invasion (Balch et al., 2009). Both
ulceration and mitotic rate have a direct relationship with metastasis and lethality;
the worse ulceration and the higher mitotic rate, the higher the risk for metastasis
and subsequent death (Edge and Compton, 2010; Grande Sarpa et al., 2006).
Histopathologically, cutaneous melanoma is classified into four main
types: superficial spreading melanoma, lentigo maligna melanoma, acral
lentiginous melanoma and nodular melanoma (Crowson et al., 2006). World
Health Organization (WHO) includes rare melanoma variants, such as
desmoplastic melanoma, in their classification (LeBoit et al., 2006). Very briefly,

16

superficial spreading melanoma is characterized by single or nested malignant
melanocytes spreading within the epidermis; lentigo maligna melanoma usual
pattern is the proliferation of atypical melanocytes, single or nested, along the
epidermal-dermal junction, that frequently extends deeply into the appendageal
epithelium; acral lentiginous melanoma is a relatively rare type of melanoma that
arises on non hair bearing plantar, palmar and subungual skin sites,
characterized by atypical melanocyte proliferation, single or nested, along the
epidermal-dermal junction; nodular melanoma share several histological features
with superficial spreading melanoma with the significant difference that they are
very sharply circumscribed (Smoller, 2006). Desmoplastic melanoma is
characterized by the proliferation of single or nested atypical melanocytes (with
spindled morphology) that tends to extend deeply into the reticular dermis (lower
layer of the dermis), and is very poorly circumscribed (Magro et al., 2006).
All main types of melanomas exist as in situ lesions (non-invasive) or
invasive, with the exception of nodular melanoma (Geisler et al., 2013). Also,
nodular melanoma lacks the radial growth phase, which leads to the sudden
appearance of a malignant neoplasm in previously normal skin (Crowson et al.,
2006). Radial growth phase (RGP) involves neoplastic melanocytes, located
intraepidermally, multiplying and dispersing as single or small group of cells.
Without further events, RGP is not capable of generating metastatic events, and
it is virtually always curable through surgery with rare exceptions (Crowson et al.,
2006). On the other hand, vertical growth phase (VGP) implies the ability of a
melanoma to metastasize. Early VGP is differentiated from the RGP by the
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occurrence of a dominant nest (25-50 cells) within the papillary dermis
(uppermost layer of the dermis); this nest has to be larger than any nest within
the epidermis or the neighboring dermis, and cytologically distinct (shape, size,
cytoplasmic or nuclear features, absence or presence of pigment) from
intraepidermal group of cells (Crowson et al., 2006). Presence of mitotic figures,
and of dominant nest that fills and wide the papillary dermis, extends to the
papillary–reticular dermal interface or

into the reticular dermis and/or

subcutaneous fat are particular characteristics of fully evolved VGP (Crowson et
al., 2006). Furthermore, VGP is subclassified by cell phenotype: spindle cell
vertical growth phase (less tendency to widespread metastasis) and epithelioid
vertical growth phase (most commonly associated with widespread metastases)
(Crowson et al., 2006).
Systematic meta-analyses of melanoma risks revealed that physical
attributes such as blue eyes, fair skin and red hair have, respectively, 1.47, 2.06,
3.64 higher relative risk of developing melanoma than dark colors (Gandini et al.,
2005). High density of freckles showed a relative risk of 2.10 (Gandini et al.,
2005). The presence of a dysplastic nevus leads to a slight increase (2-fold) in
overall risk for melanoma (Tucker et al., 1997), but the annual risk of any single
nevus becoming melanoma is quite small, less than 1 in 200,000 for both men
and women younger than 40 years old (Tsao et al., 2003). Having a primary
family member with melanoma or a parent with multiple melanomas are also
associated with higher relative risks (1.74 and 61.78, respectively) (Hemminki et
al., 2003).
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Histologically, basal cell carcinoma is derived from the basal lamina and/or
the root sheaths of the outer hair follicle (Kolk et al., 2014). The morphological
classification of BCC includes: nodular (including micronodular), infiltrative
(including sclerosing or morphemic), superficial and mixed subtype (Rippey,
1998). The WHO’s classification uses differentiating patterns to classify BCC
types: superficial, nodular, micronodular, infiltrating, fibroepithelial, basal cell
carcinoma with adnexal differentiation, basosquamous carcinoma, keratotic basal
cell

carcinoma

and

sclerosing/morpheiform,

other

variants

infundibulocystic,

which

includes

pigmented

cystic,

and

adenoid,

miscellaneous

(Kossard et al., 2006). From the point of view of simplicity and good
reproducibility, Rippey’s (1998) classification is the most acceptable. Some of the
histological features common to all these types of tumor are: basaloid cells with a
thin cytoplasm surrounding round or oval nuclei that is bigger and darker than
nuclei of epidermal keratinocytes. Mitosis and apoptotic cells are frequent.
Excluding the rare pleomorphic (giant cell) type of BCC, the majority of BCC
cases do not present cellular atypia (Calonje et al., 2012).
Basal cell carcinoma is a malignant tumor with a low mortality rate, slow
growth and rare metastasis events. However, they can be very destructive
causing, in particular, extensive local tissue damage and have a high recurrence
rate after treatment (Cockerell et al., 2011). The risk factors for BCC recurrence
include: body location (specially central part of the face, such as periocular,
perioral and nasal); large size (over 2cm); perineural and/or perivascular
invasion; prior recurrence (Samarasinghe et al., 2011). Based on the main and
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most frequent histological types, infiltrative and superficial types of BCC show
higher probability of aggressive local behavior, recurrence and subclinical
spread, in comparison to the nodular type (Rippey, 1998; Vantuchova and Curik,
2006).
Histologically, squamous cell carcinoma consists of nests, sheets and
strand of keratinocytes with variable squamous differentiation; these cells arise
from the epidermis and can extend superficially or deeply into the dermis
(Weedon et al., 2006). Squamous cell carcinoma spreads by local infiltration and
may follow tissue conducts and planes such as blood vessels, lymphatics and
nerves (Weedon et al., 2006). According to WHO, SCC subtypes are:
acantholytic, spindle-cell squamous cell carcinoma, verrucous, pseudovascular
and adenosquamous carcinoma (Weedon et al., 2006). Acantholytic SCC is
histologically defined by the loosening of the keratinocytes intercellular
attachments resulting in acantholysis (separation of keratinocytes from each
other within the epidermis); pseudovascular SCC is a very aggressive type of
SCC characterized by marked acantholysis resulting in angiosarcoma-like areas;
adenosquamous carcinoma arises from pluripotent cell related to acrosyringia
(epidermal keratinocytes around sweat gland ducts), characterized by the
formation of mucin secreting glands; spindle-cell is an uncommon type of SCC
that exhibit prominent spindle-cell morphology and is poorly differentiated;
verrucous is a rare variant of well-differentiated SCC with low metastatic
probability (Weedon et al., 2006).
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Squamous cell carcinoma is a malignant tumor responsible for the
majority of NMSC deaths. It grows relatively rapidly, with an invasive nature that
may progress to lymph nodes and distant organs metastasis (Weinberg et al.,
2007). The risk factors for SCC recurrence include tumor location (face specially
lips, and ears), size, depth, poor differentiation, perineural invasion, acantholytic
features, prior reappearance (Weedon et al., 2006; Weinberg et al., 2007).
1.7 Current Available Treatments for Melanoma
Treatment options for melanoma are based on the stage of the disease at
the time of diagnoses and include surgery, possibly followed by adjuvant therapy.
Surgery is the optimal approach and, currently, it is the only potential curative
treatment for melanoma (Geisler et al., 2013). Until recently, no adjuvant therapy
had demonstrated to be life extending. Different treatments and combinations of
treatments had been tested and none had ever demonstrated survival
improvement. Luckily, in recent years, completely new medical options have
dramatically changed melanoma treatment (Geisler et al., 2013).
Chemotherapy

regimens,

such

as

Dacarbazine

(DTIC)

and

Temozolomide, are considered “standard therapy” for advanced melanoma.
Dacarbazine, an alkylating agent that interferes with tumor cell growth, is
considered the most active single agent in patients with melanoma, and it is the
only chemotherapeutic agent approved by the Food and Drug Administration
(FDA) for treatment despite its low response rates and no indication of survival
advantage (Ives et al., 2007; Serrone et al., 2000). Whereas DTIC is
administrated intravenously, Temozolomide is an oral alkylating agent that differs

21

from DTIC by its ability to penetrate the blood-brain barrier; yet a trial comparing
both drugs showed similar response rates, progression-free survival slightly
prolonged in the Temozolomide treatment (1.9 months vs. 1.5 months) but no
statistical difference in survival (7.7 months vs. 6.4 months) was observed
(Middleton et al., 2000).
Immunotherapy is a very promising idea that consists of increasing
immune mechanisms responsible for naturally eradicating cancer cells (Mansh,
2011). Interleukin-2, a T-lymphocyte cytokine, was the first immunotherapy to be
approved by the FDA for treatment of advanced melanoma. Interleukin-2, like the
chemotherapy drug DTIC, shows low response rates even at high doses of
treatment (Agarwala, 2009; Atkins et al., 2000; Atkins et al., 1999). Furthermore,
it is associated with substantial toxicity including capillary leak syndrome,
hemodynamic instability and, high risk of infection (Antony and Dudek, 2010).
Interferon α 2-b, an adjuvant immunotherapy drug, received FDA approval in
2011 for treatment of melanoma with microscopic or gross nodal involvement.
Clinical trials showed that in patients with high-risk cutaneous melanoma, this
adjuvant treatment lead to a significant improvement in both disease-free survival
and overall survival (Mocellin et al., 2010). However, a more recent analysis did
not find a significant long-term overall survival benefit (Petrella et al., 2012).
In 2011, Ipilimumab, the first anti-CTLA-4 monoclonal antibody, was
approved by the FDA for treatment of metastatic melanoma (Traynor, 2011).
Ipilimumab enhances T-lymphocyte activity and tumor infiltration by blocking
Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) inhibitory signals, which allows
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unregulated and prolonged activation of T-lymphocytes in a non-specific manner.
Fundamentally, this drug enhances patient’s antitumor response by blocking
immune-regulatory mechanisms, which are responsible for suppressing host
responses

to

tumor-associated

antigens

(Mansh,

2011).

Clinical

trials

demonstrated an overall survival improvement in patients that had been
previously treated for metastatic melanoma; the median survival rate was 10.1
months in the Ipilimumab therapy group vs. 6.4 months in the control group (Hodi
et al., 2010). Side effects of this drug include enterocolitis, hepatitis, and
dermatitis (Hodi et al., 2010).
Another novel treatment based on directing the immune system to activate
T-lymphocytes against cancer cells is the PD-1/PDL-1 pathway inhibitors, such
as nivolumab (Patnaik et al., 2012). This anti-PD-1 monoclonal antibody is
showing promising clinical trial results, however it is not currently FDA-approved.
The ligand PDL-1 (Programmed Death Ligand-1) binds to the PD-1
(Programmed Death-1) receptor expressed in T-cells. Activation of this pathway
blocks T-cell identification and the subsequent destruction of the tumor cells (Keir
et al., 2008), which it is believed to be of advantage in tumor survival (Hirano et
al., 2005). Nivolumab phase I clinical trial revealed increase in antitumor activity
in patients with advanced malignancy, including melanoma (Brahmer et al.,
2010). Advanced melanoma patients showed a medium overall survival of 16.8
months, with 40% of patients alive at 3 years (Sznol et al., 2013). These
promising results encouraged further clinical trials. Currently, there is an ongoing
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phase III clinical trial comparing Nivolumab versus DTIC in patients with
metastatic melanoma (ClinicalTrials.gov, 2014).
Targeted therapy is characterized by the development of a drug that
inhibits specific proteins, enzymes and pathways related to cancer development
and progression. The Ras/Raf/mitogen activated protein kinase (MAPK) pathway
is one of the major signaling networks involved if melanomagenesis and
progression (Hocker et al., 2008). The B-raf proto-oncogene serine/threonine
protein kinase (BRAF) is found constitutively active in the majority of human
melanomas. BRAFV600, the most common mutated form of the BRAF gene, is
known to play a role in proliferation and survival of melanoma cells via MAPK
pathway activation (Besaratinia and Pfeifer, 2008; Davies et al., 2002).
The BRAF inhibitors are drugs that work by inhibiting the mutated BRAF
protein. Vemurafenib (PLX4720) was the first FDA-approved agent that targets
mutated BRAF (Heakal et al., 2011). It is an oral inhibitor of the mutated
BRAFV600 kinase domain that leads to a decrease in cell proliferation through the
phosphorylation of ERK (Extracellular signal regulated kinase) and Cyclin D1
(Jang and Atkins, 2013; Tsai et al., 2008). In a phase III clinical trial, untreated
patients carrying the BRAFV600E mutations received either Vemurafenib or DTIC.
Vemurafenib treatment led to significant reduction in the risk of death (63%) and
in the risk of either death or disease progression (74%) (Chapman et al., 2011).
Despite the success of Vemurafenib, most, if not all, patients ultimately develop
resistance resulting in disease progression at a median time of approximately 6
months. Multiple resistance mechanisms have been considered including the
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reactivation of MAPK pathway, which is downstream of BRAF, in a BRAFindependent manner (Swaika et al., 2014; Wagle et al., 2011).
Dabrafenib (GSK2118436) is another inhibitor of mutated BRAFV600,
recently approved by the FDA (Ballantyne and Garnock-Jones, 2013). Its
mechanism of action is similar to Vemurafenib, but it has a shorter half-life
(Hauschild et al., 2012). A clinical trial carried out in untreated patients carrying
the BRAFV600 mutations demonstrated that Dabrafenib significantly improved
progression-free survival compared with DTIC (5.1 vs. 2.7 months, respectively)
(Hauschild et al., 2012).
The MAPK pathway is immediately downstream of BRAF. For this reason,
MAPK pathway inhibitors have been investigated as monotherapy as well as in
combination with BRAF inhibitors. Trametinib (GSK1120212) a selective oral
inhibitor of MEK (Mitogen-extracellular signal regulated kinase), approved by the
FDA in 2013, showed to increase the progression-free survival in patients
carrying mutated BRAFV600 (Falchook et al., 2012). A phase III trial comparing
Trametinib with chemotherapy drugs (DTIC or Paclitaxel) showed a significant
improvement of both median progression-free survival (4.8 months vs. 1.5
months) and overall survival (81% vs. 67%) when Trametinib was used (Flaherty
et al., 2012b).
Based on the evidence that the resistance to therapy with BRAF Kinase
inhibitors is associated with reactivation of MAPK pathway, a combined treatment
of Dabrafenib (a selective BRAFV600 inhibitor) and Trametinib (a selective MAPK
inhibitor) was started. Results showed that this combination increased median
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progression-free survival (9.4 months vs. 5.8 months in the monotherapy group),
and improved the rate of complete or partial response (76% vs. 54% with
monotherapy) (Flaherty et al., 2012a). Because of these results, the use of these
two drugs in combination has received accelerated FDA approval this year
(Menzies and Long, 2014).
Endothelin receptor B (EdnrB) and Endothelin receptor A (EdnrA) are the
two G-coupled protein receptors (GPCR) that mediate physiological responses
upon endothelin ligand binding (Saldana-Caboverde and Kos, 2010). The EdnrB,
an important protein in melanocyte development, has been implicated in the
progression and metastatic capability of melanoma cells (Demunter et al., 2001;
Lahav, 2005). Blockage of this receptor by small molecule inhibitors has shown
to affect the growth and survival of melanoma cells (Bagnato et al., 2004; Lahav
et al., 1999; Lahav et al., 2004). Bosentan, a targeted drug that competitively
inhibits specific ligand binding to EdnrA and EdnrB is, consequently, an EdnrA
and EdnrB antagonist (Clozel et al., 1994). Human melanoma cell lines treated
with Bosentan showed decreased melanoma cell viability and DNA synthesis,
inhibition of proliferation, and induction of apoptosis (Berger et al., 2006). These
results instigated the testing in a clinical setting. Bosentan monotherapy was
tested in stage IV metastatic melanoma patients and it appeared to be of benefit,
achieving disease stabilization in 6 out of the 32 (19%) patients at week 6, with
confirmation at week 12; five patients were still stable after 24 weeks and two
persisted stable for longer than 2 years on study treatment (Kefford et al., 2007).
As a consequence of these positive results, a phase II randomized clinical trial
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was carried out, in a similar patient population, in combination with first-line DTIC
chemotherapy. This study revealed no beneficial effect on time to tumor
progression, progression-free survival and overall survival when Bosentan was
combined with DTIC (Kefford et al., 2010). Failure of this trial could be attributed
to the abnormally high time to tumor progression observed in the control group
and/or the strict selection criteria of patients (Kefford et al., 2010).
Advances in immunotherapy and targeted therapy have positively
transformed malignant melanoma treatment. Even though there has been
remarkable progress in the management of this disease, no existing treatment
has been completely successful. Therefore, much is needed to be learned, and
optimizations of existing therapies along with innovative therapies for recurrent
and metastatic melanoma are still necessary.
1.8 UV-Induced Melanoma Mouse Models
Experimental animal models create a unique platform that enables the
development of strategies to further elucidate pathogenesis. Genetically
engineered mouse models opened the doors for further investigations on the
relevance of UV radiation on melanomagenesis, and important information was
gained from studies employing these models. A description of available UVinduced melanoma mouse models and the rationale for their creation is reviewed
here.
Mutations in the tumor suppressor locus CDKN2A (cyclin-dependent
kinase inhibitor 2A), located at 9p21, have been mostly linked to familial
melanoma (Haluska and Hodi, 1998; Soufir et al., 2004). Yet, the CDKN2A is
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also found functionally inactivated in a significant percentage of non-familial
(sporadic) melanomas (Castellano and Parmiani, 1999). This locus encodes two
proteins, p16INK4a and p14ARF (Sharpless, 2005). p16INK4a is a Cyclin-dependent
kinase (CDK) inhibitor that specifically inhibits Cyclin-dependent kinase 4 (CDK4)
or

Cyclin-dependent kinase 6 (CDK6) complexes, consequently blocking

Retinoblastoma (RB) phosphorylation and preventing G1/S cell cycle progression
(Chin et al., 1998). p14ARF promotes p53 stabilization, which in turn can promote
cell cycle arrest in Growth phase 1 (G1) and apoptosis in response to
oncogenic stimuli (Zhang et al., 1998). Absence of functional p16INK4a and
p14ARF proteins, disrupts tumor suppression by RB and p53 pathways, and is
believed to contribute to melanomagenesis. The ablation of these proteins could
be one of the reasons why P53 protein is found mutated in a small percentage of
human melanomas (Meier et al., 1998). Furthermore, most of the melanoma
cases that have p53 mutations had no concurrent mutations in p16INK4a or p14ARF
(Hodis et al., 2012).
The first UV-induced melanoma mouse model reported used a transgenic
mouse in which the melanocyte-specific tyrosinase promoter drives expression of
the Simian virus 40 tumor antigen (SV40 T-antigen) (Klein-Szanto et al., 1994).
Expression of the transgene resulted in the inactivation of both p53 and RB
pathways, which is functionally equivalent to the loss of the CDNK2A locus
(Klein-Szanto et al., 1994). High expressers of the transgene were UV irradiated
for up to 4 consecutive days, starting at 4 days of age. These mice developed
melanomas, particularly ocular melanomas (Klein-Szanto et al., 1994). Due to
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the aggressiveness of the ocular tumors, mice did not live long enough to allow
the investigation of cutaneous melanoma with full progression (Klein-Szanto et
al., 1994). Mice that were low expressers of the transgene provided a more
significant model in which chronic neonatal UV exposure for 5 days starting at 3
days of age resulted in 26% incidence of cutaneous malignant melanoma (Kelsall
and Mintz, 1998).
The Rat sarcoma (RAS) proteins are small GTPases localized on the
internal side of the plasma membrane. They function as critical mediators of cell
growth, proliferation and differentiation (Lowy and Willumsen, 1993; Trahey and
McCormick, 1987). RAS activity is controlled through cycling between a
guanosine triphosphate (GTP)-bound state (active) and guanosine diphosphate
(GDP)-bound state (inactive) (Downward, 1996). GTP-bound RAS is able to
trigger the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling
pathway and to activate the RAS associated protein BRAF. Activated BRAF, in
turn phosphorylates and triggers the ERK signaling pathway (Marais et al., 1995;
Rodriguez-Viciana et al., 1994). Through the activation of these effectors, RAS
proteins regulate cell survival, proliferation and differentiation. Neuroblastoma
RAS viral (v-ras) oncogene homolog (NRAS) is the most commonly mutated
RAS isoform in human melanoma (15-20%) whereas Harvey rat sarcoma viral
oncogene homolog (HRAS) and Kirsten rat sarcoma viral oncogene homolog
(KRAS) mutations are rare (1-2%) (Milagre et al., 2010). The most frequent RAS
mutations are found at codons for glycine 12 (G12), glycine 13 (G13) or
glutamine 61 (Q61). These mutations lead to the disruption of RAS intrinsic
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GTPase activity, locking it into a constitutively activated state in which RAS
stimulates downstream effectors, even in the lack of ligands that bind specific
membrane receptors (Barbacid, 1987; Bos, 1989). Approximately 77% of the
KRAS mutants involve G12, whereas over 80% of the NRAS and HRAS
mutations involve Q61 (Milagre et al., 2010). Mutations in BRAF gene are found
in approximately 66% of human melanomas (Davies et al., 2002). In melanomas
carrying BRAF mutations, 92% occurs in a single codon valine 600 (V600)
(Besaratinia and Pfeifer, 2008).
The Tyr::HrasG12V (Tpras) mouse also serves as a UV-induced melanoma
mouse model. This transgenic mouse has the activated human T-24 Ha-ras gene
expressed under the control of the tyrosinase promoter, which targets the
transgene to melanocytes (Powell et al., 1995). The Tpras mice exhibit
melanocytic hyperplasia and/or hyperpigmentation. Although they do not develop
spontaneous cutaneous melanoma (Powell et al., 1995), a low percentage
develop ocular melanoma (Kramer et al., 1998). The Tpras mice are highly prone
to developing malignant melanoma even after a single neonatal dose of UV
radiation (Hacker et al., 2005); however, they do not develop melanoma by
chronic adult UV exposure (Broome Powell et al., 1999). Neonatal exposure of
Tpras in a CDK4R24C/R24C -null background (mutation that makes this kinase
insensitive to p16/Ink4a inhibition) (Rane et al., 1999) greatly decreases age of
onset and enhances melanoma aggressiveness (Hacker et al., 2006). Another
Tyr::HrasG12V transgenic mouse (the regulatory region used to create the
transgene was slightly different than the one used for the Tpras mouse) on a
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p19ARF (p14ARF mouse analog)-null background showed a significant decrease in
melanoma latency and an increase in penetrance upon neonatal UV-exposure
when compared to non UV-exposed mice (Kannan et al., 2003). In sharp
contrast, this enhancement was not observed in neonatal UV-exposed
Tyr::HrasG12V homozygous for p16INK4a deficiency (Kannan et al., 2003),
suggesting that a defect in the p53 pathway may be required for UV-induced
melanoma. However, analyses of melanoma lesions from Tyr::HrasG12V; p19ARF-/revealed that nearly 50% of the tumors presented amplification of CDK6 and loss
of p16INK4a, leading to the conclusion that UV-induced melanoma arises
exclusively on Tyr::HrasG12V when both p53 and RB pathways are disrupted
(Sharpless et al., 2003).
Analyses of hereditary melanomas that carry germline p16INK4a mutation
revealed that 95% of these patients presented NRAS mutation at codon Q61
(Eskandarpour et al., 2003). A mouse model with NRASQ61K mutation was
developed and it consists of melanocytic expression of NRASQ61K under the
control of the tyrosinase promoter, Tyr::NrasQ61K (Ackermann et al., 2005). This
transgenic mouse presents a hyperpigmented skin phenotype and, at low
percentages (29%) and long latency (~1 year), develops spontaneous melanoma
(Ackermann et al., 2005). A significant increase in melanoma penetrance (94%)
and a decrease in melanoma latency (~6 months) are observed when
Tyr::Nras Q61K is on a CDKN2A-deficient background (Ackermann et al., 2005).
Tyr::Nras Q61K carrying a CDK4R24C/R24C null homozygous mutation also develops
spontaneous melanoma, and a single neonatal UV dose significantly decreases
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the age of onset and increases tumor penetrance (Hacker et al., 2010).
Treatment of Tyr::NrasQ61K; CDK4R24C/R24C neonatal mice with Dimericine (a T4
endonuclease V liposome lotion known to accelerate the removal of DNA
damage induced by UV radiation) prior to UV-exposure do not lead to significant
difference in the onset of melanoma development (Hacker et al., 2010),
suggesting that neonatal UV-initiated melanomas may be driven by other
mechanisms besides the large CPD load and/or their inefficient repair (Hacker et
al., 2010).
Mutations in proteins of the NER pathway such as XPA and XPC, and
subsequent reduced DNA photodamage repair capacity, result in high indices of
skin cancer, including melanoma (Kraemer et al., 1987). In view of that, attempts
to generate UV-dependent melanoma mouse models based on NER deficiency
were made in order to elucidate the underlying pathogenic mechanisms. Chronic
UVB exposure of Xpa null homozygous adult mice did not lead to melanoma
development, however it did lead to the development of other forms of skin
cancer (Nakane et al., 1995). When Xpa and Ink4a/Arf targeted mutations were
combined in a pigmented hairless background mouse and subjected to different
UVB exposure regimens, an increased amount of UV-induced nevi was
observed, but none of the Xpa-/-; Ink4a/Arf-/- developed melanoma (van Schanke
et al., 2006). In another study, Stem Cell Factor transgenic (SCF-Tg) mice, which
have epidermal melanocytes and are hyperpigmented, carrying a homozygous
null Xpa mutation were repeatedly exposed to UV radiation (3 times a week for
10 weeks, starting at 8-10 weeks of age). Melanoma was observed in 33% of the
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irradiated mice and, out of those, 55% showed local metastasis (Yamazaki et al.,
2005).
In an Ink4a/Arf deficient background, the loss of Xpc protein leads to a
significant increase in melanomagenesis rates after a single neonatal dose of UV
radiation (Yang et al., 2007). A recent study carried out with transgenic mice that
have BRAFV600E mutated gene expressed under the mouse tyrosinase enhancer
and promoter, revealed that loss of p19ARF enhances neonatal UVB-induced
melanomagenesis by transcriptionally repressing Xpc and, consequently
reducing DNA repair damage (Luo et al., 2013).
In a very recent published study, BRAFV600E melanocytic expression was
induced in transgenic mice at 2 months of age with the intention of representing
somatic mutation acquisition (Viros et al., 2014). One month later these mice
started to be UV-exposed weekly, mimicking mild sunburn in humans, for a
period of 6 months. During these exposures, some mice had their back partially
covered with UV-proof cloth or topically treated with sunscreen. Results revealed
that UV radiation significantly increases melanomagenesis in mice carrying the
BRAFV600E mutation, that application of UV-proof cloth or sunscreen delayed the
onset of UV-induced melanoma, and sunscreen protection leads to reduction in
the number of melanomas in UV-exposed BRAFV600E transgenic mice. In
addition, some p53 mutations that were previously identified in humans are found
in the melanoma lesions of these mice, suggesting a direct role of UV radiation in
the creation of p53 mutations in melanomas (Viros et al., 2014). In humans,
primary and metastatic melanomas have low incidences of p53 point mutations
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or allelic loss; however p53 loss is frequently associated to melanoma
progression (Yang et al., 2001).
One of the most well recognized UV-induced melanoma mouse models is
the Hepatocyte Growth Factor/Scatter Factor (HGF/SF) transgenic mouse
(Noonan et al., 2000; Noonan et al., 2001). This model is very successful
because of the amount of major similarities it has with human melanoma, such
as the requirement of neonatal UV radiation recapitulating the critical childhood
sunlight exposure in melanoma development (Whiteman et al., 2001), adult
exposure as an additional factor (Autier and Dore, 1998) and general melanoma
histopathological features (Smoller, 2006). In the HGF/SF transgenic mouse, the
metallothionein-gene promoter drives the overexpression of HGF/SF to a wide
variety of tissues. The HGF/SF binds to the receptor tyrosine kinase Met,
promotes melanocyte proliferation and migration, which leads to accumulation of
large numbers of melanocytes in the dermis, epidermis and dermal–epidermal
junction, similar to their distribution in human skin (Takayama et al., 1996). These
mice spontaneously develop melanoma with the mean age onset of
approximately 21 months. Chronic UV-exposure of these transgenic mice do not
accelerate melanomagenesis in comparison with non UV-exposed mice;
however it induces the development of non-melanocytic tumors such as
squamous cell carcinomas, squamous papillomas and sarcomas (Noonan et al.,
2000). In contrast, a single neonatal erythemal dose to 3.5 day old HGF/SF mice
induces cutaneous melanoma with significantly reduced latency and most of
these lesions histologically resemble human lesions at various stages of
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progression, including metastasis (Noonan et al., 2001). Exposure of HGF/SF
neonates to a second UV erythemal dose at 6 weeks, does not accelerate
melanomagenesis, however it significantly increases the number of melanocytic
lesions arising per mouse as well as the incidence of non-melanocytic tumors
(Noonan et al., 2001). The rates of neonatal UVB-induced melanoma
appearance in pigmented HGF (Noonan et al., 2012) and albino HGF transgenic
mice (De Fabo et al., 2004) are not significantly different. However, melanomas
are initiated by UVA in pigmented HGF (Noonan et al., 2012) but not in albino
FVB-HGF mice (De Fabo et al., 2004). These results suggested that the initiation
of melanoma by UVB is pigment independent whereas melanoma induction by
UVA is completely pigment dependent. Analyses of direct DNA damage in
pigmented and albino mice after either neonatal UVB-exposure or UVA-exposure
revealed that amounts of CPD formation were not significantly different between
pigmented and albino mice, suggesting that UV-induced CPD formation was not
the reason for the difference in melanoma induction between pigmented and
albino animals. Analyses of indirect DNA damage revealed a strikingly increased
amount of oxidative DNA damage in pigmented mice after UVA-exposure but not
in albino mice; and the production of oxidative DNA damage required both UVA
and melanin (Noonan et al., 2012). In conclusion, these results showed that the
presence of melanin (> 90% eumelanin and < 10% pheomelanin) is a
requirement for melanoma induction by UVA, but not UVB in HGF/SF transgenic
mice (Noonan et al., 2012). The inverse of this result was observed when albino
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HGF/SF transgenic neonatal mice are UV-exposed; in this case UVB, but not
UVA, was found to be the melanomagenic waveband (De Fabo et al., 2004).
Deletion of the Nonmetastatic 23 (Nm23) gene, the first metastasis
suppressor gene to be described, in neonatal UV-exposed HGF/SF transgenic
mice led to the development of melanomas with aggressive metastatic potential
especially to the same organs observed in human melanoma metastasis, such
as lymph nodes, lung and liver (Jarrett et al., 2013). Another study showed that a
single neonatal erythemal UV dose of HGF/SF mice carrying a null Ink4a/Arf
mutation, significantly decreased melanomagenesis median onset to just 50 days
versus the 238 days observed in HGF/SF mice with wild type Ink4a/Arf (Recio et
al., 2002). An experiment carried out in HGF/SF transgenic mice with
CDK4R24C/R24C null mutation, revealed that a single neonatal UV dose decreases
the latency and accelerates the growth of primary melanomas resulting in a
significant reduction in the time between melanoma onset and death (61 days vs.
96 days). Moreover, lung metastases are more frequently observed in UVirradiated than in the untreated cohort of HGF/SF; CDK4R24C/R24C mice (73% vs.
47%) (Gaffal et al., 2011). In a recently published study, the carcinogen DMBA
(7,12-dimethylbenz(a)anthracene) was applied in the dorsal skin of adult
HGF/SF; CDK4R24C/R24C mice to first initiate melanomagenesis and afterwards
these primary cutaneous melanomas were UV-exposed twice a week for a period
of 6 weeks (Bald et al., 2014). Results revealed that UV radiation of the skin
stimulates keratinocytes to release the High Mobility Group 1 (HMGB1) cytokine
leading to the recruitment and activation of neutrophils to the skin and initiation of
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inflammatory response. This inflammatory environment is believed to stimulate
angiotropism and promote the migration of melanoma cells, which results in
metastasis (Bald et al., 2014). This result complements the findings that UVRinduced inflammation promotes melanomagenesis in neonatal mice via
interferon-γ secretion by recruited macrophages (Zaidi et al., 2011). interferon-γ
was believed to be beneficial to an innate immune system defense against
cancer, however now it is believed that, under specific circumstances, it may
instead promote melanomagenesis (Zaidi and Merlino, 2011).
Twenty years ago, the first UV-induced melanoma mouse model (KleinSzanto et al., 1994) was reported. Since then, several models were developed
based on different signaling pathways that have been associated to
melanomagenesis. Studying these models revealed different mechanisms by
which these specific pathways could lead to melanomagenesis. An important
pathway that, up to now, has not been explored for the creation of a melanoma
mouse model is the Endothelin signaling pathway. The signaling pathway of
Endothelin 3 (Edn3) ligand and its seven-transmembrane receptor EdnrB is
essential for many aspects of melanocyte development. In vitro studies
demonstrated that Edn3 markedly increases the proliferation of pluripotent neural
crest cells, stimulates the production of large numbers of melanocyte precursors
and eventually leads to their differentiation as pigmented cells (Lahav et al.,
1996; Opdecamp et al., 1998; Reid et al., 1996; Stone et al., 1997). Many studies
infer that the Edn3/EdnrB signaling pathway regulates several processes in the
development of different types of cancers such as ovarian, pulmonary, colorectal,
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cervical, breast cancer, and also malignant melanoma (Bagnato et al., 2004).
The association of this pathway with the progression and metastatic potential of
melanoma cells has been reported (Bagnato and Natali, 2004; Lahav et al.,
2004; Rosano et al., 2004). Melanoma cell lines treated with the EdnrB specific
antagonist BQ788 showed increased apoptosis and increased Vascular
Endothelial Growth Factor gene expression. In vivo, administration of BQ788 to
immunocompromised mice slowed down human melanoma tumor growth by
decreasing cell viability (Lahav et al., 1999; Lahav et al., 2004). Treatment of
melanoma cells with Endothelin 1 (Edn1) and Edn3 results in downregulation of
E-cadherin, and upregulation of N-cadherin and matrix metalloproteinases, which
are important for cell-cell adhesion and cell-cell communication. These results
could be linked to the disruption of normal tumor-host interactions and
progression of cutaneous melanoma (Bagnato et al., 2004; Rosano et al., 2004).
Gene expression analysis of metastatic melanoma cells from tissue biopsies
revealed an abnormal upregulation of the EDN3 gene. Further, an increase in
metastatic melanoma cell survival was observed Edn3-treated cells in vitro (Tang
et al., 2008).
Although experiments on genetically modified mice have provided us with
a better understanding of how UV radiation can initiate and stimulate progression
in melanoma, novel UV-induced mouse models are in need to be developed to
help fill out the vast amount of gaps that still exists, in order to optimally fight this
life-threatening malignancy.
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1.9 Research Questions
Melanomagenesis is influenced by environmental and genetic factors as
well as tumor-host interactions. There is great amount of evidence that UV
radiation exposure has a major impact in DNA damage and other molecular
events, and that UV acts as a carcinogen with both initiating and promoting
properties. It is commonly accepted in cancer biology that transcription factors
and signaling pathways that direct the development of a specific cell lineage will
most likely be deregulated in transformed cells that descend from that cell
lineage during the process of tumorigenesis. One of the critical pathways that
regulate various aspects of melanocyte development, the Edn3/EdnrB signaling
pathway, has also been associated with melanoma progression (SaldanaCaboverde and Kos, 2010). The NER pathway repairs photoproducts induced by
UV radiation and its disruption leads to skin carcinogenesis, including melanoma
(Yarosh et al., 2005). Given that over-activation of the Edn3/EdnrB signaling
pathway may be involved in the malignant progression and metastatic spread of
melanoma and that DNA damage caused by UV radiation is a causative agent in
melanoma development, my research questions directly address if UV radiation
exposure combined with NER loss and over-activation of the Edn3/EdnrB
pathway can lead to melanomagenesis:
Question #1: Is UV exposure of transgenic mice that express Endothelin 3 under
the Keratin 5 (K5) promoter sufficient for melanoma development?
Our laboratory generated transgenic mice that produce excessive Edn3 by
epidermal keratinocytes throughout development (K5-Edn3) (Garcia et al., 2008).
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These mice have hyperpigmented skin as a result of the accumulation of large
numbers of melanocytes in the epidermal/dermal junction where they are not
normally found (Garcia et al., 2008). This condition could serve as the basis for
melanocytic tumor formation and, upon neonatal UV exposure, I hypothesize that
K5-Edn3 transgenic mice will develop melanoma.
Question #2: Does NER disruption affect melanoma penetrance and latency in
UV-exposed transgenic mice that express Endothelin 3 under the K5 promoter?
The Xpa and Xpc proteins have important roles in the NER pathway
(Cleaver et al., 2009; Ortonne, 2002). It is well established that mutations in this
pathway reduces DNA photodamage repair capacity, resulting in high indices of
skin cancer, including melanoma (Kraemer et al., 1987). Thus, I hypothesize that
Xpa or Xpc deficiency will result in increased penetrance and a decreased
latency in the UV-induced melanoma mouse model.
Question #3: What is the mutation profile of melanoma lesions that arise in UVexposed transgenic mice that express Endothelin 3 under the K5 promoter?
UV-induced DNA damage causes typical genetic mutations, C to T and CC to
TT transitions, called "UV signature mutations”. This type of mutations is prominently
found in human cutaneous melanoma (Berger et al., 2012; Pleasance et al., 2010).
Several human cancers, including melanoma, present mutations in the three human
RAS genes (NRAS, KRAS, HRAS) (Ball et al., 1994; Omholt et al., 2002) and,
mutations in the RAS effector protein BRAF have been identified in 66% of melanoma
patients (Davies et al., 2002). Interestingly, mutations found in BRAF and NRAS
genes in human melanomas are not UV-signature mutations (Hodis et al., 2012). I
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hypothesize that lesions removed from K5-Edn3 UV-induced melanoma mouse
model will present, but not restrictively, UV signature mutations in some of these
genes.
Question #4: How does the timing of UV exposure affect melanomagenesis?
Epidemiological data suggest that melanoma development results from
intense and intermittent UV doses, particularly during childhood (Whiteman et al.,
2001). Results obtained from various mouse models support the notion that
childhood sunburns constitute a major melanoma risk factor (Hacker et al., 2005;
Noonan et al., 2001). Since neonatal murine skin has higher percentage of
melanocytic progenitor cells than the skin of adult mice (Hirobe, 1984), when UVirradiated, these cells can acquire DNA photodamage that would lead to DNA
mutations, resulting in melanomagenesis later on in life. I hypothesize that a
single neonatal UV dose is essential for melanoma development and that a
second exposure, during adult stage, will cause an increase in melanoma
penetrance and, mainly a decrease in melanoma latency. Further, I expect that
mice exposed to UV radiation only at the adult stage will not develop melanoma.
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Figure 1.1 The effects of UV radiation on the human skin. Schematic of UV rays
passing through the ozone layer and reaching the human skin. Keratinocytes
represent 95% and melanocytes represent 1-2% of the cells that constitute
human epidermis. UV light is subdivided in three wavelengths: UVC, UVB, and
UVA. UVC (below 280 nm) is completely blocked by the ozone layer. Minimum
amounts of UVB (280-320m) are capable of passing through the ozone layer and
penetrate the first layers of skin. Most of UVA (320-400nm) is able to reach earth’
surface and it can penetrate deeply into the skin. UVA and UVB can directly lead
to the formation of pyrimidine dimers, whereas indirect absorption by UVA can
lead to reactive oxygen species formation. Localization of different types of cells
that give rise to melanoma (melanocytes) SCC and BCC (keratinocytes).
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Figure 1.2 Ways in which UV radiation can give rise to skin cancer. Genetic
predisposition added to the harmful UV radiation effects enhances the probability
of skin carcinogenesis development.
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Figure 1.3 Relationship of skin type, UV radiation and skin cancer risk.
Individuals with fair skin have low epidermal melanin levels, almost never tan,
and burn easily after UV exposure. These phenotypes are associated with high
predisposition of skin cancer development. Individuals with darker pigmented
skin tend to tan easier rather than burn and are less likely to develop skin
carcinogenesis.
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II. NOVEL UV-INDUCED MELANOMA MOUSE MODEL DEPENDENT ON
ENDOTHELIN 3 SIGNALING
2.1 Published Paper Information
This chapter has been published as a Letter to the Editor in the Pigment
Cell and Melanoma Research Journal volume 27 issue 5, pages 839-842.
2.2 Letter to the Editor
Dear Editor,
Melanomagenesis is closely associated with early exposure to ultraviolet
(UV) radiation and the development of UV-responsive animal models has
contributed to the elucidation of UV radiation effects on carcinogenesis. To our
knowledge, all previously established mouse models of neonatal UV-induced
melanoma, carry loss or gain of function mutations in the melanocytes, and
develop lesions spontaneously that are enhanced by UV exposure (Kannan et
al., 2003; Noonan et al., 2001). Hence, it is important to generate a mouse model
that develops lesions exclusively upon neonatal UV exposure, and whose
melanocytes are not transformed a priori.
Here we report the development of a melanoma mouse model dependent
solely on the presence of Endothelin3 (Edn3) in the tumor microenvironment and
neonatal UV radiation.
The Endothelin 3 (Edn3) - Endothelin receptor B (EdnrB) pathway is
essential for melanocyte development, and has been associated with increased
risk of different types of cancers including melanoma (Bagnato et al., 2004).
Previously, our laboratory reported the generation of the K5-tTA; TRE-Edn3-lacZ
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(for simplicity, K5-Edn3) mice (Garcia et al., 2008). The skin of newborn and
adults K5-Edn3 mice is extremely dark when compared to non-transgenic
littermates. This hyperpigmentation is due to the over-activation of Edn3 under
the control of the K5 promoter, which consequently led to the accumulation of
large numbers of melanocytes in the dermis and dermal-epidermal junction of the
skin where they are not normally found.
Photoproducts induced by UV radiation are, in normal cells, repaired by
the nucleotide excision repair (NER) pathway. Malfunction of this pathway is an
important factor in UV-induced skin cancer. Xeroderma Pigmentosum (XP)
patients have a defective NER and are at a much higher risk, up to 1,000 times,
of developing skin cancers, including melanoma (Kraemer et al., 1994). This
disease results from mutations in the components of the NER pathway, such as
XPA. Interestingly, mice lacking the Xpa gene were highly sensitive to UVinduced nevi and exhibited a high incidence of squamous cell carcinoma after
exposure

to

UVB,

however

UVB

exposure

alone

did

not

lead

to

melanomagenesis (Nakane et al., 1995; van Schanke et al., 2006).
To determine if neonatal UV-exposure would lead to melanomagenesis in
mice that have over-activation of Edn3 and Xpa deficiency, a total of 76 mice, 39
experimental (Xpa-/-; K5-Edn3, Xpa+/-; K5-Edn3, Xpa+/+; K5-Edn3), and 37
controls (Xpa-/-, Xpa+/-, Xpa+/+) (Table 1), were exposed to UV radiation (see
Supporting Information 2.3). Melanocytic lesions were not observed in the control
group. Animals carrying the K5-Edn3 transgene developed lesions that were
diagnosed by histopathology and immunofluorescence as melanoma (Figure 1B-
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D) or blue nevi (Figure 1F-H). Grossly, melanoma lesions appeared as
hyperpigmented spots that began to grow and often became ulcerated (Figure
1A). These lesions were found on the ventral (46.7%) and dorsal (33.3%)
aspects of the torso, as well as on the face (20%) of the mice, and their
localization was independent of the genotype. Similarly, blue nevus-like lesions
(Figure 1E) were found on the ventral (33.3%) and dorsal (50.0%) torso, and face
(16.7%) of the mice.
The histopathological analysis of the lesions revealed that melanomas
appeared to have arisen from blue nevus-like lesions. The foci of most
melanomas were comprised of atypical cells in clusters extending into the
subcutis. The cells were crowded, with overlapping large nuclei and one to few
nucleoli. The melanocytes contained fine melanin granules and there were
several associated melanophages. One case showed a nevoid melanoma, fairly
well circumscribed, and composed of a cluster of melanocytes in nests. The cells
were uniform and bland and did not show maturation. Pigment was present in the
deep aspect of the lesion and several mitotic figures were found. Blue nevus-like
lesions were broad based and comprised of horizontally oriented dendritic
melanocytes predominantly confined to the dermis. Frequently they wrapped
around appendages. The melanocytes contained fine melanin granules and
small bland nuclei. Most cases were comprised predominantly of melanophages,
which were polygonal in shape and contained coarse melanin granules.
Immunostaining analysis using antibody against S100 revealed that
melanoma lesions were heavily stained in comparison to blue nevus-like lesions
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(Figure 1C, G). Since proliferation rates are frequently used as a cancer
prognosis marker, we verified if there was a quantitative difference between the
melanoma and the blue nevus-like lesions. The mean proliferation rate, assessed
by quantification of Ki67 positive cells out of the total number of cells, was
significantly higher (p=0.034) in melanoma lesions (1.31 ± 0.37) than in blue
nevus-like lesions (0.22 ± 0.05) (Figure 1D, H, J).
Exposure of neonatal Xpa+/+; K5-Edn3 transgenic mice to UV radiation
was sufficient to induce melanomagenesis. However, the percentage of Xpa-/-;
K5-Edn3 melanoma-bearing animals was remarkably higher (60%) than the
Xpa+/-; K5-Edn3 (46.2%) and Xpa+/+; K5-Edn3 (18.75%) (Table 1). Additionally,
the average time of melanoma appearance was significantly different (p=0.013)
between Xpa-/-; K5-Edn3 (29.62 ± 5.47) and Xpa+/-; K5-Edn3 (43.81 ± 10.08),
although a significant difference was not observed in comparison to Xpa+/+; K5Edn3 (56.57 ± 31.64).
The melanoma free-survival period of Xpa-/-; K5-Edn3 mice was
significantly shorter (p=0.029, Kaplan-Meier with log-rank test) than that of
Xpa+/+; K5-Edn3. However, the melanoma free-survival period for Xpa+/-; K5Edn3 was not significantly different from that of Xpa-/-; K5-Edn3 or Xpa+/+; K5Edn3 (p=0.231 and p=0.358, respectively) (Figure 1I). Blue nevus like lesions,
bearing a striking similarity to human blue nevi, were observed in 10% of Xpa-/-;
K5-Edn3, 30.8% of Xpa+/-; K5-Edn3 and 43 .75% of the Xpa+/+; K5-Edn3 (Table
1). Nodal nevi were observed in 58.33% of the mice with blue nevi (Figure S1C,
D). All mice that developed melanoma also presented enlarged and
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hyperpigmented lymph nodes that contained several clusters of Trp1 positive
cells (Figure S1A, B). These findings indicate that the combination of UV, Xpa
deficiency and over-expression of Edn3 in the skin lead to the formation of
melanomas that have the capacity of local metastasis.
The impact of UV radiation on the development of nevi and melanoma
lesions has also been studied in mice lacking Xpa in combination with Ink4a/Arf
deficiency. Pigmented hairless Xpa-/-; Ink4a/Arf-/- mice developed many blue nevi
but rarely melanoma even after neonatal or repetitive adult UVB exposure (van
Schanke et al., 2006). In another study, pigmented Xpa-/-; SCF-Tg mice were
found to develop melanoma after repetitive exposure to high doses of UV
radiation during adulthood; however, melanomas infrequently metastasized to
lymph nodes (Yamazaki et al., 2005). In our study, after one neonatal dose of UV
radiation, K5-Edn3 with and without Xpa deficiency developed melanoma and
fully penetrant lymph node metastasis. Although Xpa deficiency was not
essential for melanomagenesis, it did have a major impact on the frequency and
time of appearance of melanoma lesions.
In order to better understand the relationship between DNA repair
deficiency, apoptosis, and cancer susceptibility, we analyzed UV-induced
apoptosis in Xpa-/-; K5-Edn3 and Xpa+/-; K5-Edn3 mice. Neonatal mice (3.5 days
of age) were exposed to UV radiation and their dorsal skin was removed after 24
hours. Cleaved Caspase-3 positive cells were quantified in the epidermis and
dermis (Figure S2A, B.). Results revealed that the total numbers of epidermal
apoptotic cells in Xpa-/-; K5-Edn3 were significantly greater (p=0.00032) than
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those of Xpa+/-; K5-Edn3; however, this difference was not significant when the
dermal numbers of apoptotic cells were compared. Interestingly, the dermal
number of apoptotic melanocytes, and more dramatically the epidermal numbers,
were significantly higher (p=0.02675 and p=0.00429, respectively) in Xpa-/-; K5Edn3 than in Xpa+/-; K5-Edn3 mice (Figure S3C). The unexpected large number
of apoptotic cells in the animals carrying the K5-Edn3 transgene may result from
the phototoxic and photosensitizing effects of melanin (Noonan et al., 2012;
Wood et al., 2006). Our findings suggest that in our heavily pigmented mouse
model, melanin did not act as a protective factor; instead it acted in a harmful
way accelerating melanoma development and progression.
Higher penetrance and decreased latency of melanomas were observed
in the mice carrying heterozygous or homozygous mutations in Xpa, despite of
the fact that the numbers of apoptotic melanocytes were also larger in these
animals. These results suggest that the apoptotic differentiated melanocytes may
not be the cell of origin of the melanomas. One possibility is that these tumors
arise from undifferentiated cells residing in the skin or hair follicles and follow the
stem

cell

hypothesis

of

tumorigenesis

(Grichnik,

2008).

Furthermore,

undifferentiated melanocyte precursors present in the skin or hair follicles may
respond to the higher levels of apoptosis by increasing their proliferation rate to
compensate for dying cells. This would in turn lead to a higher frequency of
mutations in these highly proliferative Xpa deficient cells and result in earlier
melanoma appearance (Queille et al., 2001).
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This new model of melanomagenesis will serve as a useful tool to further
explore the deleterious effects of UV radiation in tumorigenesis and for the
evaluation of possible therapeutic agents.
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Table 1. Lesions observed in UV-irradiated neonatal mice of different genotypes
H&E/ IHC Diagnosed
Others
Lymph Node
Blue
Nodal
Genotype
n
Melanoma
Metastasis
Nevus Nevus A B C D
-/Xpa ; K5-Edn3
10
6
6
1
1
0 1 0 0
13
6
6
4
2
0 0 1 0
Xpa+/-; K5-Edn3
+/+
16
3
3
7
4
0 0 0 0
Xpa ; K5-Edn3
Controls
37
0
0
0
0
1 0 0 2
A- Squamous cell carcinoma; B- Sarcoma; C- Fibroma; D- Fibrohistiocytic Tumor
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Figure 2.1 Lesions in UV-irradiated K5-Edn3 transgenic mice. (A)
Representative melanoma skin lesion found in the ventral torso of a 12 month-old
Xpa+/-; K5-Edn3 mouse. (E) Representative blue nevus lesion found in the dorsal
torso of an 18 month-old Xpa-/-; K5-Edn3 mouse. Hematoxylin and eosin staining
of a 5μm paraffin section of a melanoma (B) and blue nevus lesion (F) (higher
magnification in insets). Immunofluorescence staining of melanoma (C, D) and
blue nevus (G, H) 10μm cryosections with S100 (1:200, Dako, Carpinteria, CA)
and Ki67 (1:100, Abcam, MA) , respectively. Propidium iodide (PI) (C, G) and
Hoechst (D, H) were used as counterstain. (I) Cumulative survival of melanomafree mice as a function of age (Kaplan–Meier analysis) in UV-irradiated K5-Edn3
and non-K5-Edn3 mice with and without Xpa deficiency. The melanoma freesurvival period of Xpa-/-; K5-Edn3 (n=10) mice was significantly shorter (p=0.029,
Kaplan-Meier with log-rank test) than that of Xpa+/+; K5-Edn3 (n=16). The
melanoma free-survival period for Xpa+/-; K5-Edn3 (n=13) was not significantly
different than that of Xpa-/-; K5-Edn3 or Xpa+/+; K5-Edn3 (p=0.231 and p=0.358,
respectively, Kaplan-Meier with log-rank test). In the absence of K5-Edn3
transgene (n=37), mice failed to develop melanoma. (J) Quantification of Ki67
positive cells in melanoma (n=3) and blue nevus-like (n=3) lesions. Bars
represent means ± SD. Statistical differences were calculated by one-way
ANOVA (p<0.05, n=3 per melanocytic lesion).
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2.5 Supporting information
2.5.1 Materials and Methods
2.5.1.1 Mice
K5-tTA; TRE-Edn3-lacZ (for simplicity, K5-Edn3) mice were generated in
our laboratory (Garcia et al., 2008). The skin of newborn K5-Edn3 mice is
extremely dark when compared to non-transgenic littermates, and remains
hyperpigmented into adulthood. This hyperpigmentation is due to the
accumulation of large numbers of melanocytes in the epidermis, dermis and
junction of the skin where they are not normally found.
Xpa knockout mice (courtesy of Dr. Friedberg, University of Texas
Southwestern Medical Center, Dallas, Texas) were crossed with K5-Edn3
double-transgenic mice to generate Xpa+/-; K5-Edn3 mice. Treatment and control
mice were produced from Xpa+/-; K5-Edn3 intercrosses. Genotyping was carried
out according to previously published protocols (de Vries et al., 1995; Garcia et
al., 2008). All mice used in this study were housed in the Animal Care Facility at
Florida International University (Miami, FL). All animal studies were carried out in
accordance with Institutional Animal Care and Use Committee (IACUC)
regulations.
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2.5.1.2 Induction of Skin Tumors by UV Radiation
A bank of six Phillips F40 UV lamps (Q Panel Lab Products, Cleveland,
OH) was used. The UV dose was continuously monitored with a IL1700
radiometer (UV Process Supply, Inc., Chicago, IL). Neonatal mice (3.5 days old)
were subjected to a single erythematous dose of UV radiation in single wells of a
6-well Falcon plastic tissue culture plate (Becton-Dickinson, NJ) without the lid
(Noonan et al., 2001). Following UV exposure, animals were monitored weekly
for skin lesions and tumor development during a period of 18 months. The time of
appearance of the first skin lesion that subsequently became melanoma was
recorded for each mouse and used in a Kaplan-Meier survival analysis.
2.5.1.3 Histological and Immunostaining Analysis of Tumors
At the time of necropsy, mice were grossly assessed for the presence of
metastases. Melanomas and melanoma metastases were diagnosed based on a
combination of histomorphology and immunostaining. For histomorphology,
tissues were fixed in 10% buffered formalin, paraffin-embedded, sectioned at 5
microns, and stained with hematoxylin and eosin. For immunostaining analyses,
tissues were fixed in 4% paraformaldehyde, embedded in freezing medium (OCT
Compound for Cryostat Sectioning, Ted-pella, USA), and cryosectioned
longitudinally at 10 microns. Cryosections of skin lesions were stained with
antibodies against S100 (1:200 dilution, Dako, Carpinteria, CA) and Trp1 (1:50
dilution, α-PEP1 antibody, Dr. Vincent Hearing - NIH) whereas lymph nodes were
only stained with antibody against Trp1. Sections were visualized on a Leica
Leitz DMRB fluorescent microscope. Digital pictures were captured with a Leica
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DC 500 camera. Pathological analysis was carried out blind with respect to the
animals’ genotype.
2.5.1.4 Proliferating Cells
Melanoma and blue nevus-like skin biopsies were cryosectioned
longitudinally (10μm) and immunostained with the antibody against Ki67 (dilution
1:100, Abcam, MA). Ki67 positive cells were counted in 25 sections of each skin
biopsy (n=3 per melanocytic lesion type).
2.5.1.5 Apoptotic Cells
Neonatal mice (3.5 days old) were UV-irradiated for 15 minutes, as
previously described, and sacrificed 24 hours later. Dorsal skin biopsies were
cryosectioned longitudinally (10μm) and immunostained with the antibody against
cleaved Caspase-3 (dilution 1:100, Cell Signaling, Boston, MA). Apoptotic cells in
the epidermis and dermis were counted in 30 sections for each genotype (n=3
per genotype).
2.5.1.6 Statistical Analysis
Kaplan-Meier curves were generated for the analyses of tumor incidence
between genotypes. Statistical differences were calculated by log-rank test and
one-way ANOVA. Sunburn cells results were analyzed using a one-way ANOVA.
Values of p<0.05 were considered statistically significant.
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Figure S1. Lymph nodes in UV-irradiated K5-Edn3 transgenic mice. (A)
Hyperpigmented and enlarged cervical lymph node diagnosed as local
metastasis removed from Xpa+/-; K5-Edn3 mouse showed in Figure 1A. (C)
Hyperpigmented and enlarged brachial lymph node diagnosed as nodal nevus
removed from Xpa-/-; K5-Edn3 mouse showed in Figure 1E. Immunofluorescence
staining of lymph nodes cryosections with antibody against TRP1 (B, D).
Propidium iodide (PI) was used as counterstain.
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Figure S2. Distribution of melanin and quantification cleaved Caspase-3 positive
cells in neonatal UV-irradiated dorsal skin. Newborns (3.5 days old) were
exposed to 15 minutes of UV radiation and sacrificed 24 hours later for dorsal
skin removal. Melanin (A, dark) and cleaved Caspase-3 (B, green) distribution in
a dorsal skin cryosection of an Xpa-/-; K5-Edn3 mouse. Hoechst was used as
counterstaining. Double labeled cells (arrows) were counted as apoptotic
melanocytes. (C) Quantification of cleaved Caspase-3 positive cells in epidermis
and dermis of Xpa-/-; K5-End3 (n=3) and Xpa+/-; K5-End3 (n=3). Bars represent
means ± SD. Statistical differences were calculated by one-way ANOVA (p<0.05,
n=3 per genotype).
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III. NUCLEOTIDE EXCISION REPAIR DEFFICIENCY ENHANCES MELANOMA
PHOTOCARCINOGENESIS IN TRANSGENIC K5-EDN3 MICE

3.1 Abstract
Melanomagenesis is influenced by the interaction of environmental and
genetic factors, as well as, tumor-host interactions. Mice with Xpc deficiency
show high sensitivity to ultraviolet (UV) light, leading to skin cancer development,
except melanoma. The Endothelin 3 (Edn3) signaling pathway is essential for the
development of melanocyte precursor cells. In humans, this pathway has also
been implicated in melanoma progression and its metastatic potential. The
purpose of the present study was the development of a UV-induced melanoma
mouse model that combines Xpc deficiency with the over-activation of the Edn3
pathway. To this end, transgenic mice over-expressing Edn3 under the control of
the Keratin 5 promoter (K5-Edn3) and carrying a targeted mutation in Xpc were
exposed to a single suberythemal neonatal dose of UV radiation. A subgroup of
mice was additionally exposed to a second dose of UV radiation at 6 weeks of
age. One more group of animals was exposed to a single dose of UV only at 6
weeks of age. Animals were monitored weekly for skin lesion development during
the period of at least 18 months. Histomorphology and immunostaining were
used to confirm the melanocytic origin of primary skin tumors. Melanoma was
only found in animals with the K5-Edn3 transgene. Increased penetrance and
decreased latency were observed in animals exposed to one dose of UV
radiation that were Xpc null in comparison to Xpc heterozygous or Xpc wild type.
Animals exposed to two doses of UV radiation (at 3.5 days and 6 weeks of age)
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did not reveal significant differences in melanoma penetrance or average time for
melanoma appearance between Xpc null, Xpc heterozygous or Xpc wild type.
Mice exposed to UV radiation only at 6 weeks of age did not develop melanoma.
Quantification of UV-induced photodamage in the dorsal skin of 3.5 days old UVirradiated mice revealed a decreased number of thymine-dimer positive cells in
the K5-Edn3 skin in comparison to the skin of non K5-Edn3. Next generation
sequencing of two melanoma skin lesions revealed several mutations in Braf,
Nras, Kras and Hras amplicons. These results indicate that combination of
neonatal UV exposure with over-activation of the Edn3 pathway is sufficient to
lead for melanomagenesis in mice, and lack of Xpc enhances its development.
3.2 Introduction
Melanoma is the most aggressive form of skin cancer, notorious for its
high propensity to metastasize and poor response to current treatment
modalities. The incidence rates of melanoma have considerably increased for the
past several decades and it is estimated that approximately 65% of the
worldwide and 90% of North America cutaneous malignant melanoma are linked
to ultraviolet (UV) radiation as a causal agent (Armstrong and Kricker, 1993).
Development of UV-responsive animal models has contributed to the
elucidation of the interactions between UV effects and melanoma formation and
progression. Transgenic mice expressing either activated H-ras (Broome Powell
et al., 1999) or SV40 T-antigen (Kelsall and Mintz, 1998; Klein-Szanto et al.,
1994) under the regulation of a melanocyte specific promoter (TPras or TyrSV40Tag) capable of developing melanocytic hyperplasia or spontaneous
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melanoma, respectively, showed an increased melanoma penetrance when
submitted

to

chronic

UV

exposures.

These

transgenic

mice

were

hyperpigmented with accumulation of melanocytes in the skin. This seems to be
a requirement for UV-induced melanomagenesis in mice, most likely because in
adult skin, melanocytes are normally restricted to hair follicles where they are
protected from the damaging effects of UV.
One of the most successful UV-induced melanoma mouse models is the
transgenic mouse that over-expresses the tyrosine kinase receptor Met ligand,
Hepatocyte Growth Factor/Scatter Factor (HGF/SF), ubiquitously under the
control of the metallothionein promoter. These mice are hyperpigmented with
large numbers of melanocytes found at or near the dermal-epidermal junction,
similar to their distribution in human skin. They develop metastatic melanomas
spontaneously, but at very low incidence and long latency (Takayama et al.,
1997). Chronic suberythemal UV exposure of these mice did not alter the kinetics
of melanomagenesis (Noonan et al., 2000). However, a single neonatal dose of
suberythemal UV was sufficient to induce melanomas with high penetrance,
short latency, and histopathological features that resembled those of human
melanomas (Noonan et al., 2001). Additionally, other studies using the same
neonatal UV exposure regimen showed that TPras (Hacker et al., 2005) and TyrHras: Arf-/- (Kannan et al., 2003) mice have a dramatic increase in melanoma
penetrance in comparison to chronic UV treatments or unexposed adult mice
with the same genotype, respectively. These studies validated retrospective
epidemiological data suggesting that in contrast to other skin cancers that are
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linked with cumulative lifetime UV exposure, cutaneous malignant melanoma is
caused by intense intermittent UV exposure, especially during childhood
(Whiteman et al., 2001). A recent study addressing the role of UV radiation in a
mouse model in which melanocytes express BRAFV600E demonstrated that UV
protection, such as sunscreen and UVR-proof cloth, does help against UVinduced melanoma. The use of sunscreen was shown to delay the onset age and
to reduce the number of melanomas in UV-exposed BRAFV600E transgenic mice.
Furthermore, p53 gene was identified as a UV-targeted gene in melanoma
lesions removed from these mice, and p53 mutations were often linked to faster
melanoma formation (Viros et al., 2014).
The DNA damage caused by UV radiation can lead to mutations in critical
genes encoding for proteins related to DNA repair, apoptosis and cell cycle
control. Malfunction of these important proteins are strongly connected with early
stages of skin cancer (Ortonne, 2002). Photoproducts induced by UV radiation
are, in normal cells, repaired by the nucleotide excision repair (NER) pathway,
highlighting its essential role in the maintenance of integrity of genomic DNA after
it has been exposed to environmental damage (Friedberg et al., 1995). Indeed,
NER malfunction is an important factor in UV-induced skin cancer (Yarosh et al.,
2005). The prominent role of NER in cancer resistance is well exemplified by
patients with Xeroderma Pigmentosum (XP). The XP disease is an autosomal
recessive disease where patients have a defective NER and a much higher risk,
up to 1,000 times, of developing skin cancers, including melanoma (Kraemer et
al., 1994). This disease results from mutations in the components of the NER
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pathway, such as Xpa and Xpc. Mice lacking the Xpa gene were highly sensitive
to UV-induced nevi and exhibited a high incidence of squamous cell carcinoma
after exposure to UVB (Nakane et al., 1995; van Schanke et al., 2006). However,
melanomas only developed when the skin of Xpa-/- mice was topically treated
with DMBA and chronically exposed to UV (van Schanke et al., 2006). Mice
lacking the Xpc gene are likely to develop esophageal, bladder and lung cancer
when exposed to chemical carcinogens (Hollander et al., 2005). They are also
very susceptible to UV-induced basal and squamous cell carcinomas (Friedberg
et al., 1999; Sands et al., 1995; Venema et al., 1991).
Several human cancers, including melanoma, present mutations in the three
human RAS genes (NRAS, KRAS, HRAS) (Ball et al., 1994; Omholt et al., 2002).
Additionally, mutations in the RAS effector protein BRAF have also been identified in
66% of melanoma patients (Davies et al., 2002). Disrupted NER pathway allows UV
radiation to trigger gene mutations. Studies carried out in XP patients showed that
approximately 50% of the patients present RAS mutations in skin cancers. This is
twice of the percentage observed in skin cancer patients that do not have XP
disease (Daya-Grosjean et al., 1993).
The Endothelin 3 (Edn3) cytokine and its seven-transmembrane receptor
Endothelin receptor b (Ednrb) are essential for melanocyte development, and
have been associated with increased risk of different types of cancers such as
breast cancer, prostate cancer, and malignant melanoma (Bagnato et al., 2004).
Experiments using the Ednrb specific antagonist, BQ788, showed that
decreasing Ednrb levels in malignant melanoma can inhibit the growth of
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melanoma cell lines both in vitro and in vivo by enhancing apoptosis and
stimulating angiogenesis via upregulation of Vascular Endothelial Growth Factor
(Lahav et al., 1999; Lahav et al., 2004). The activation of Ednrb by Endothelin 1
(Edn1) and Edn3 in melanoma cell lines led to changes in cadherins, connexins,
integrins and matrix metalloproteinases that are associated with the disruption of
normal host-tumor interactions and progression of cutaneous melanoma
(Bagnato and Natali, 2004; Rosano et al., 2004).
In order to further understand the relationship among UV radiation, genetic
factors and tumor microenvironment, we established a novel UV-induced
melanoma mouse model that depends exclusively on the presence of Edn3 in
the tumor microenvironment and it is exacerbated by Xpa deficiency (Benaduce
et al., 2014). In this study we describe how Xpc deficiency affects melanoma
initiation and progression and how important the timing of UV radiation exposure
is to melanomagenesis.
3.3 Materials and Methods
3.3.1 Mice
K5-tTA; TRE-Edn3-lacZ (for simplicity, K5-Edn3) mice were originally
developed in our laboratory (Garcia et al., 2008). The K5-Edn3 newborn skin is
extremely dark when compared to non-transgenic littermates, and remains
hyperpigmented into adulthood. This hyperpigmentation is the result of the
accumulation of large numbers of melanocytes in the epidermis, dermis and
epidermal-dermal junction of the skin where they are not normally found.
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The Xpa and Xpc knockout mice (courtesy of Dr. Friedberg, University of
Texas Southwestern Medical Center, Dallas, TX) were crossed with K5-Edn3
transgenic mice to generate Xpa+/-; K5-Edn3 and Xpc+/-; K5-Edn3 mice,
respectively. Treatment and control mice were produced from intercrosses of
Xpa+/-; K5-Edn3 and Xpc+/-; K5-Edn3. DNA was extracted from tail biopsies and,
genotyping was performed according to previously published protocols (Cheo et
al., 1997; de Vries et al., 1995; Garcia et al., 2008). All mice used in this study
were housed in the Animal Care Facility at Florida International University
(Miami, FL). All animal experiments were carried out in accordance with
Institutional Animal Care and Use Committee (IACUC) regulations.
3.3.2 Induction of Skin Tumors by UV Radiation
A bank of six Phillips F40 UV lamps (Q Panel Lab Products, Cleveland,
OH) was used in the experiments. The UV radiation dosage was continuously
monitored with a IL1700 radiometer (UV Process Supply, Inc., Chicago, IL).
Neonatal mice (3.5 days old) were exposed to a single erythematous dose of UV
radiation in single wells of a 6-well Falcon plastic tissue culture plate (BectonDickinson, NJ) without the lid (Noonan et al., 2001). A group of mice was further
exposed to a second dose of UV radiation of 30 minutes at 6 weeks of age;
whereas another group of mice was exclusively exposed to a 30 minutes dose of
UV radiation at 6 weeks of age. Twenty-four hours prior to the 6 weeks of age
exposure, the dorsal aspect of the animals were gently depilated with Veet
(Reckitt Benckiser Inc., Parsippany, NJ). Following UV exposure, animals were
monitored weekly for skin lesions and tumor development for at least 18 months.
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The time of appearance of the first skin lesion that subsequently became
melanoma was recorded for each mouse and used in a Kaplan-Meier survival
analysis.
3.3.3 Histological and Immunostaining Analysis of Tumors
At the time of necropsy, mice were meticulously evaluated for the
presence of melanoma metastases. Melanoma was diagnosed based on a
combination of histomorphology and immunostaining. For histomorphology,
tissues were fixed in 10% buffered formalin, paraffin-embedded, sectioned at 5
microns, and stained with hematoxylin and eosin. For immunostaining analyses,
tissues were fixed in 4% paraformaldehyde, embedded in freezing medium (OCT
Compound for Cryostat Sectioning, Ted-pella, USA), and cryosectioned
longitudinally at 10 microns. Cryosections of skin lesions were washed with PBS
pH 7.4, incubated 10% goat serum (Life Technologies, NY), 0.1% Triton X-100
(Sigma, MO) in 1X PBS (pH 7.4) for 1 hour and 15 minutes at room temperature.
Sections were then incubated overnight, at 4oC, with antibody against S100
(1:200 dilution) (Dako, CA; cat#Z0311). Cryosections were then washed three
times with PBS (pH 7.4) and incubated for 1 hour, at room temperature, with
Alexa Flour 488 Goat Anti-Rabbit (1:200, Invitrogen, NY; cat#A11008) and
counterstained with Propidium Iodide. Sections were visualized on a Leica Leitz
DMRB fluorescent microscope. Digital pictures were taken with a Leica DC 500
camera. Pathological analysis was carried out blind with respect to the animals’
genotype.
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3.3.4 Thymine-Dimer Detection
Neonatal mice (3.5 days old) were UV-irradiated for 15 minutes, as
previously described, and sacrificed 24 hours later. Dorsal skin biopsies were
fixed in 4% paraformaldehyde, embedded in freezing medium (OCT Compound
for Cryostat Sectioning, Ted-pella, USA), and cryosectioned longitudinally at 10
microns. Antigen-retrieval was performed by heating 5mM Tris – 1mM EDTA
buffer solution (pH 8.0) for two minutes in the microwave, followed by addition of
slides to the boiling buffer and cooking them for 20 minutes in a 100oC water
bath. After cooling down for 60 minutes at room temperature, slides were washed
with PBS and incubated with 10% fetal bovine serum, 10% goat serum, 5% BSA
and 0.1% Triton X-100 in PBS (pH7.4) for 1 hour and 15 minutes. Subsequently,
cryosections were incubated overnight, at 4oC, with anti-thymine dimer
monoclonal antibody (dilution 1:50) (Kamiya Biomedical, Seattle, WA; cat#MC062) and washed three times with PBS (pH7.4). Following 1 hour incubation with
Alexa Flour 488 Goat Anti-mouse (1:1000, Invitrogen, NY; cat#A011001) and
counterstained with Hoechst. Sections were visualized on a Leica Leitz DMRB
fluorescent microscope. Digital pictures were taken with a Leica DC 500 camera.
Thymine-dimer positive cells were counted in 10 different sections, 5 fields of
view (magnification of 200X) per section, for each genotype (n=3 per genotype).
ImageJ software (Schneider et al., 2012) was used to count thymine dimer
positive cells and also the total number of cells identified by Hoechst.
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3.3.5 Detection and Analyses of Melanoma Mutations
Two skin lesions diagnosed as melanomas removed from two different K5Edn3 transgenic mice exposed to two doses of UV radiation were sequenced. RNA
was extracted from frozen biopsies using TRIzol Reagent (Life Technology, NY).
Concentration

and

purity

of

RNA

was

assessed

using

a

nanodrop

spectrophotometer (ND-3000, NanoDrop, Thermo Scientific, IL). RNA samples
were subjected to reverse transcription’-PCR (Maxima First Strand cDNA Synthesis
Kit for RT-qPCR, Thermo Scientific, IL), following the manufacturer’s protocols.
Bovine serum albumin (500μg/mL, New England BioLabs, MA) was added to the
reaction to counteract possible melanin PCR inhibition effects. Polymerase chain
reaction was used to amplify regions of Braf, Kras, Nras, Hras genes, using the
following primers: Braf (369bp) (forward 5’-TCATGGGCTATTCTACAAAGCCACA
AC-3’; reverse 5’-CGTCTGACTGAAAGCTATACGGGTTTTTA-3’), Kras (432bp)
(forward 5’-CGCGGCGCGGAGAGAG-3’; reverse 5’-CCTTGCTAACTCCTGAGC
CTGTTTC-3’), Nras (428 bp) (forward 5’-GGAGTTTGAGGTTTTTGCTGGTGTG3’; reverse 5’-GCCAGTTCGTGGGCTTGCTTT-3’), Hras (420 bp) (forward 5’GATTGGCAGCCGCTGTAGAAGCT-3’; reverse 5’-GGTCCTGGGCCTGCCGA3’). The correct sizes of the amplicons were confirmed on 2% agarose gels with DNA
visualized with Ethidium Bromide (Fisher Scientific, MA; cat#BP1302). DNA
concentration and quality was determined using a nanodrop spectrophotometer
(ND-3000, NanoDrop, Thermo Scientific, IL). Braf, Kras, Nras, Hras gene mutations
were detected by Ion-Torrent next generation (Ion Torren Personal Genome Machine,
Life Technology, NY) sequencing of the PCR products.
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Data were analyzed using NextGENeTM software (v2.3.4, SoftGenetics
LLC, State College, PA). The raw data from Ion Torrent were quality-filtered and
trimmed to remove bad-quality reads and adaptors. The high-quality sequence
reads were aligned to reference sequences of the PCR amplified regions used in
Ion panel.

The alignment was then performed using a parameter of a 85%

minimum read match to reference sequence with 30bp seed size.
mutant read coverage was selected for variant identification.

A >=5%

NextGENeTM

assigns a Phred-like confidence score to each variant. This score takes into
account multiple variables to calculate the likelihood of a given variant being true
instead of being caused by sequencing or alignment error.

A minimum

confidence score of 10, which corresponds to an accuracy of 90% that the
variant is true, was applied as a threshold for the mutations in this study.
3.3.6 Statistical Analysis
Kaplan-Meier curves were generated for the analyses of tumor incidence
between genotypes. Statistical differences were calculated by log-rank test and
one-way ANOVA. Thymine-dimer cells results were analyzed using a one-way
ANOVA. Values of p<0.05 were considered statistically significant.
3.4 Results
3.4.1 NER Deficiency Exacerbates UV-Induce Melanomagenesis in Neonatal
K5-Edn3 Transgenic Mice
In accordance with previously published data, exposure of neonatal K5Edn3 transgenic mice to one erythemal dose of UV radiation was sufficient for
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melanoma development (Benaduce et al., 2014). Additionally, melanomagenesis
was independent of the subsequent erythemal dose at 6 weeks of age (Table 1).
Diagnosis of melanocytic lesions as melanoma (Figure 1) was carried out
via histopathology and confirmed by immunofluorescence using the S100
marker. Mice in the control group, that did not carry the K5-Edn3 transgene, did
not present any type of melanocytic lesion (Table 1).
At the gross anatomical level, melanoma lesions on mice exposed to a
single neonatal erythemal dose of UV radiation, started as hyperpigmented spots
that kept growing overtime and frequently became ulcerated. These lesions were
situated on the dorsal (64.29%) and ventral (35.71%) aspects of the torso. Body
localization of lesions was genotype-independent.
The histopathologic analysis revealed three patterns. There were two
cases of in-situ melanomas, two nevoid melanomas and the vast majority
appeared to have originated from blue nevus like dermal lesions. As a result of
extensive ulceration, the epidermis and dermal epidermal junction was not
available for evaluation in most cases. In one case of invasive melanoma, the
dermal epidermal junction was preserved. There were foci of confluent
melanocytes at the dermal epidermal junction with upward migration, pagetoid
spread, of the melanocytes. The invasive component showed atypical cells
extending into the subcutis (Figure 1N, O). Other cases of invasive melanoma
showed extension to the underlying skeletal muscle. The cells were crowded with
overlapping large nuclei and few nucleoli. Fine melanin granules were present
and mitoses were infrequently found (Figure 1B, C). The nevoid melanomas
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were composed of nests of melanocytes in a cluster. The cells were deceptively
bland with abundant amphopilic cytoplasm, centrally located nuclei with small
nucleoli. Features favoring the malignant nature of the lesions were lack of
maturation, mitotic figures and pigment at the base (Figure 1F, G). The two
cases of in situ melanoma showed clusters of atypical melanocytes, some of
which showed pigmentation, along the junction of the hair follicle and dermis,
which is comparable to the same phenomenon at the dermal epidermal junction
(Figure 1J, K).
In animals exposed to two doses of UV radiation, melanocytic lesions also
started as hyperpigmented spots that began to grow; however these lesions
ulcerated much faster and were more severe. Because most of the melanocytic
lesions removed from these animals were extremely excoriated, it was not
possible to accurately diagnose these lesions as melanoma or not. As a result,
melanoma penetrance was remarkably reduced in animals exposed to two doses
of UV radiation and did not show any significant differences between treatments
(Table 1).
In 3.5 day old mice exposed to a single UV radiation dose, the percentage
of Xpc-/-; K5-Edn3 melanoma-bearing animals was extremely higher (66.67%)
than the Xpc+/-; K5-Edn3 (31.58%) and Xpc+/+; K5-Edn3 (15.38%) (Table 1). Yet,
the average time of melanoma appearance was not significantly different
between treatments, Xpc-/-; K5-Edn3 (19.40 ± 12.57), Xpc+/-; K5-Edn3 (23.33 ±
7.44), Xpc+/+; K5-Edn3 (41.07 ± 24.95).
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The melanoma free-survival period of Xpc-/-; K5-Edn3 mice exposed to a
single neonatal dose of UV radiation was significantly shorter than that of Xpc+/-;
K5-Edn3 (p=0.020) and Xpc+/+; K5-Edn3 (p=0.001) exposed to one single dose
(Kaplan-Meier with log-rank test). Furthermore, the melanoma free-survival
period of the neonatal exposed Xpc-/-; K5-Edn3 was significantly shorter than that
for Xpc+/-; K5-Edn3 (p=0.029) and for Xpc+/+; K5-Edn3 (p=0.018) exposed to two
doses of UV radiation (3.5 days and at 6 weeks of age) (Kaplan-Meier with logrank test). Melanoma free-survival period for Xpc-/-; K5-Edn3 exposed to a single
neonatal dose or to two doses of UV radiation was not significantly different
(p=0.058, Kaplan-Meier with log-rank test) (Figure 2). The average time of
melanoma appearance on mice exposed to two doses of UV radiation was also
not significantly different among Xpc-/-; K5-Edn3 (16.48 ± 10.97), Xpc+/-; K5-Edn3
(20.05 ± 10.00), Xpc+/+; K5-Edn3 (27.85, just one case was observed).
Similar to the trend observed in our previously published data (Benaduce
et al., 2014), the average time of melanoma appearance on mice exposed to two
doses of UV radiation was significantly shorter in Xpa-/-; K5-Edn3 (19.52 ± 6.97)
in comparison to Xpa+/-; K5-Edn3 (35.19 ± 3.07) and Xpa++-; K5-Edn3 (74.19 ±
0.54) (p=0.023 and p= 0.005, respectively). Additionally, a significant difference
was also found between Xpa+/-; K5-Edn3 and Xpa+/+; K5-Edn3 (p=2.69E-05). On
the other hand, the melanoma free-survival period was not significantly different
between these treatments (Figure 3).
Melanoma development was not observed in any of Xpa-/-; K5-Edn3 (n=4),
Xpa+/-; K5-Edn3 (n=4) or Xpa+/+; K5-Edn3 (n=5) mice exposed to UV radiation
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just at 6 weeks of age. This result confirms the importance of neonatal UV
radiation exposure for melanoma initiation.
Our data suggest that the combination of neonatal UV radiation with Xpc
deficiency intensifies melanoma development in mice over-expressing Edn3 in
the skin.
3.4.2 K5-Edn3 Transgenic Mice Skin Shows Decreased Levels of Direct
DNA Photodamage
Given that only mice carrying the K5-End3 transgene with the
hyperpigmentation phenotype developed melanoma, we decided to compare the
amount of DNA photodamage in the skin by comparing the levels of the thyminedimer formation in K5-Edn3 and non K5-Edn3 UV-exposed mice. Neonatal mice
(3.5 days of age) were exposed to a single erythemal dose of UV radiation and
their dorsal skin was removed after 24 hours. Quantification of thymine-dimer
positive cells revealed that the total numbers of photodamaged cells in K5-Edn3
newborn skin were significantly smaller (p=0.00084) than those of non K5-Edn3
skin (Figure 4I). In K5-Edn3 dorsal skin the majority of CPDs were found in areas
with low melanin levels and mostly concentrated in the epidermis with few
positive cells found in upper layers of the dermis (Figure 4A, C, E, G). Non K5Edn3 skin showed CPD formation throughout the epidermis and dermis (Figure
4B, D, F, H).
3.4.3 Melanoma Mutations Screening
We screened two melanoma lesions removed from two distinct K5-Edn3
mice exposed to two doses of UV radiation, for mutations in Braf, Kras, Nras and
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Hras genes. Twenty-eight mutations, with mutation score above 25, were found
(Table 2). Increased amount of mutations were observed in Hras gene (60.71%)
in comparison to Braf (14.29%), Kras (14.29%) and Nras (10.71%). Kras gene
presented the only UV-signature mutation found; however this mutation did not
lead to an amino acid modification. Insertion (71.43%) or deletion (25%) of a
single nucleotide was the most frequent form of mutation found. All of these
mutations led to early stop codons and, possibly, to non-functional proteins.
3.5 Discussion
Over the past two decades, the influence of UV radiation on melanoma
development has been assessed using different light sources and protocols to
promote the malignant transformation of melanocytes in organisms carrying
different genetic modifications. Previous studies using the same neonatal UV
exposure used in this study showed a dramatic increase in melanoma
penetrance of exposed mice in comparison to unexposed mice of the same
genotype (Hacker et al., 2005; Kannan et al., 2003; Noonan et al., 2001; Recio et
al., 2002). The K5-Edn3 mouse model differs greatly from previous published
models because it neither carries oncogenic Ras-related genes in their
melanocytes nor spontaneously develops melanoma. Most importantly, it
develops cutaneous melanoma exclusively upon neonatal UV radiation.
The results obtained with the K5-Edn3 mouse model further corroborates
epidemiological data which suggest a link between childhood sunburn and the
development of malignant melanocytic lesions later on in life (Whiteman et al.,
2001).
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Epidemiological studies also indicate that dark human skin is less
sensitive to UV-induced carcinogenesis, including melanoma, when compared to
fairer skin (Del Bino and Bernerd, 2013; Del Bino et al., 2013; Diepgen and
Mahler, 2002). The K5-Edn3 mice are highly pigmented and still capable of
developing melanoma. At first this would seem to contradict the epidemiological
data but it is possible that K5-Edn3 mice on an albino (no melanin) or lethal
yellow background (low levels of eumelanin) will be more prone to developing
melanoma than the ones used for this study.
Consistent with the epidemiological studies demonstrating that NER
deficiency leads to significant higher levels of skin carcinogenesis (DiGiovanna
and Kraemer, 2012), the K5-Edn3 mice with Xpc deficiency exposed to a single
neonatal dose of UV radiation showed enhanced melanoma penetrance and
decreased latency in comparison to animals that had partial (Xpc+/-) or
completely functional (Xpc+/+) NER pathway. The impact of Xpc loss on
melanoma development was studied in mice carrying Ink4a/ARF deficiency. In
these neonatal UV-exposed mice, Xpc loss lead to a significant increase in
melanomagenesis rates in comparison to the wild type equivalent (Yang et al.,
2007). A recent study reported that loss of ARF sensitizes BRAFV600E mice to
neonatal UVB-induced melanomagenesis by reducing NER due to the inhibition
of XPC expression (Luo et al., 2013). In the UV-induced K5-Edn3, Xpc deficiency
was not a requirement for melanomagenesis after neonatal UV exposure;
however it did influence the melanoma penetrance and age of onset.
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Ultraviolet-exposure of adult K5-Edn3 (6 weeks) did not lead to
melanomagenesis and, unexpectedly, when it was associated with previous
neonatal exposure, higher melanoma penetrance was not observed. We believe
that there might have actually been a decrease in melanoma latency but the
speed and level of tumor ulceration was so high that proper diagnosis was
jeopardized. It is also important to point out that animals exposed to two doses of
UV radiation, at 3.5 days and at 6 weeks, presented more severe inflammation
than animals exposed with a single neonatal dose. Recent published results
have demonstrated how inflammatory response may underlie melanoma initiation
and progression (Bald et al., 2014; Zaidi et al., 2011). Inflammatory environment
was linked to angiotropism stimulation, promotion of melanomagenesis via
interferon-γ secretion by macrophages and the migration of melanoma cells,
which results in metastasis (Bald et al., 2014; Zaidi et al., 2011).
Ultraviolet radiation induces the formation of di-pyrimidine lesions, such as
cyclobutane pyrimidine dimers (CPDs: thymine-dimer, cytosine-dimer) (Setlow
and Carrier, 1964), and this type of DNA damage is repaired by the NER
pathway (Rastogi et al., 2010). The dorsal skin of K5-Edn3 newborn mice
exposed to UV had markedly reduced number of thymine-dimer positive cells
when compared to non K5-Edn3 skin. There are two possible explanations for
this result: (1) overexpression of Edn3 in the skin stimulates DNA repair and/or
(2) the protective effects of melanin. Previous studies demonstrated an
association between the Endothelin axis and DNA repair. Endothelin 1 (Edn1),
another EdnrB ligand such as Edn3, is believed to reduce UV-induced DNA
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photoproducts, thus implying an involvement of this cytokine in enhancement of
NER (Vlachostergios and Papandreou, 2013). Experiments carried out in mice
revealed that upon UV exposure, numbers of CPD positive cells were greatly
inhibited in Xpa null; SCF-Tg in comparison to Xpa null mice. No significant
differences were observed between these mice when chemically treated with
DMBA, instead of exposed to UV radiation. These results showed that epidermal
melanin has a protective effect against UVB-induced DNA damage but not
against chemical damage (Yamazaki et al., 2004). It appears tough that the
amounts or types of melanin may modulate its protective role and even change it
into a harmful factor (Cadet and Douki, 2011; Cadet et al., 2009). Recent studies
analyzing the effects of UV radiation in albino and pigmented HGF/SF transgenic
mice revealed that the presence of melanin is a requirement for UVA-induction of
oxidative DNA damage and this indirect DNA damage is the cause of melanoma
development in pigmented HGF/SF mice (Noonan et al., 2012). No differences
were observed in the amount of DNA damage between these two groups of mice
when exposed to UVB radiation (Noonan et al., 2012). These results revealed
that melanin presence could be the cause for melanoma initiation upon UVA
exposure, but not UVB (Noonan et al., 2012).
Ultraviolet-induced DNA damage causes typical genetic mutations, C to T and
CC to TT transitions, called UV-signature mutations. These types of mutations are
prominently found in human cutaneous melanoma (Berger et al., 2012; Pleasance et
al., 2010). Next generation sequencing of melanoma lesion biopsies removed from
K5-Edn3 exposed to two doses of UV radiation revealed one UV-signature mutation
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in the Kras gene. This mutation did not lead to amino acid modification and,
consequently, did not affect protein structure. All other mutations found were either
insertions or deletions and led to early stop codon formation. A more extensive
mutational analysis of the lesions in the K5-Edn3 by whole exome sequencing is
necessary. We expect that such analysis may reveal mutations in other well known
melanoma related genes such as Pten, p53 and Cdkn2a, and possibly, in genes that
have not previously been associated with melanoma. The K5-Edn3 neonatal model
will serve as an excellent tool to guide the identification of molecular UV targets and
further our understanding of the role played by UV in the process of tumorigenesis. It
will also be a useful platform for testing the efficacy of new compounds against
melanoma in pre-clinical studies.
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Table 1. Lesions observed in UV-irradiated neonatal mice of different
genotypes
H&E/ IHC Diagnosed
UV

Genotype

n

Melanoma

Melanoma %

1X

Xpc-/-; K5-Edn3

9

6

1X

Xpc+/-; K5-Edn3

19

1X

Xpc+/+; K5-Edn3

1X

Others
A

B

C

D

E

66.67

0

1

0

0

0

6

31.58

0

0

0

0

0

13

2

15.38

0

0

0

0

0

Controls

34

0

0

0

0

0

0

2

2X

Xpc-/-; K5-Edn3

12

3

25

0

0

0

0

0

2X

Xpc+/-; K5-Edn3

13

3

23.08

0

0

0

0

0

2X

Xpc+/+; K5-Edn3

8

1

12.50

0

0

0

0

0

2X

Controls

22

0

0

1

0

1

0

0

2X

Xpa-/-; K5-Edn3

14

3

21.43

1

0

0

0

0

2X

Xpa+/-; K5-Edn3

14

3

21.43

0

0

0

0

0

2X

Xpa+/+; K5-Edn3

15

3

20

0

0

0

0

0

2X

Controls

25

0

0

1

0

0

0

0

A- Squamous Cell Carcinoma; B- Sarcoma; C- Fibroma; D- Fibrohistiocytic Tumor;
E- Pilomatrichoma
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Figure 3.1 Melanoma lesions in UV-irradiated K5-Edn3 transgenic mice. (A)
Representative melanoma skin lesion found in the dorsal torso of a 7 month-old
Xpc-/-; K5-Edn3 mouse exposed to a single neonatal dose of UV radiation. (B)
Hematoxylin and eosin staining of a 5μm paraffin section of the lesion showing
eroded epidermis, dermis with a dense collection of pigmented melanocytes
extending beyond the subcutis into the underlying skeletal muscle. (C) Higher
magnification of B showing melanoma invading between muscle bundles. (D)
Substantial amount of immunofluorescence staining observed in the melanoma
cryosection stained for the S100 melanoma marker (green). Propidium iodide
(PI) (red) was used as counterstain. (E) Representative melanoma skin lesions
found in the dorsal torso of a 4 month-old Xpc-/-; K5-Edn3 mouse (I) and in the
face of 9 month-old Xpc+/+; K5-Edn3 a mouse exposed to UV radiation at 3.5
days of age and at 6 weeks of age. (F, G and H) Hematoxylin and eosin staining,
and S100 immunofluorescence staining displaying the nevoid melanoma found in
E and the (J, K, L and P) in situ melanoma found in I. (F) Beneath an ulcerated
epidermis is a nodule composed of nests of deceptively bland melanocytes
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extending into the subcutis. Cells have abundant cytoplasm with small centrally
located nuclei. There is lack of maturation. (G) Higher magnification of F displays
nuclei with nucleoli and mitotic figure (black arrow). (H) S100
immunofluorescence staining of the melanoma cryosection showing heavy S100
staining. (J) The epidermis overlying the hair follicle is eroded. Confluent clusters
of atypical melanocytes, many of them heavily pigmented, at the junction
between the hair follicle and dermis; atypical cells are morphologically similar to
those in B. (K) Higher magnification of J showing overlapping and crowded
melanocytes with prominent nucleoli. (L and P) S100 immunofluorescence
staining of the melanoma cryosection showing S100 positive cells at the junction
between the hair follicle and dermis. (M) Representative melanoma skin lesions
found in the left lateral of a 15 month-old Xpa+/-; K5-Edn3 mouse exposed to UV
radiation at 3.5 days of age and at 6 weeks of age. (N) Hematoxilin and eosin
staining confluence of melanocytes with pagetoid spread (yellow arrow). The
dermis shows a blue nevus like lesion. (O) Higher magnification of N shows
dermis replaced by atypical melanocytes which extend into the subcutis.
Pigmented cells are present at the base of the lesion.
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Figure 3.2 Cumulative survival of melanoma-free mice as a function of age
(Kaplan–Meier analysis) in UV-irradiated K5-Edn3 and non-K5-Edn3 mice with
and without Xpc deficiency. The melanoma free-survival period of Xpc-/-; K5Edn3 mice exposed to a single neonatal UV dose was significantly shorter than
that of Xpc+/-; K5-Edn3 (p=0.020) and Xpc+/+; K5-Edn3 (p=0.001) (Kaplan-Meier
with log-rank test). The melanoma free-survival period for Xpc-/-; K5-Edn3 was
also significantly different than that of Xpc+/-; K5-Edn3 or Xpc+/+; K5-Edn3 that
were exposed to UV radiation at 3.5 days and at 6 weeks of age (p=0.029 and
p=0.018, respectively, Kaplan-Meier with log-rank test). In the absence of K5Edn3 transgene, mice failed to develop melanoma.
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Figure 3.3 Cumulative survival of melanoma-free mice as a function of age
(Kaplan–Meier analysis) in UV-irradiated K5-Edn3 and non-K5-Edn3 mice with
and without Xpa deficiency. The melanoma free-survival period for Xpa-/-; K5Edn3 exposed to two doses of UV radiation (3.5 days and 6 weeks of age) was
not significantly different than that of Xpa+/-; K5-Edn3 or Xpa+/+; K5-Edn3
(p=0.883 and p=0.470, respectively, Kaplan-Meier with log-rank test); Xpa+/-; K5Edn3 was also not significantly different from Xpa+/+; K5-Edn3 (p=0.632, KaplanMeier with log-rank test). In the absence of K5-Edn3 transgene, mice did not
develop melanoma. K5-Edn3 mice with and without Xpa deficiency exposed to
an UV erythemal dose at adult stage (6 weeks of age), also failed to develop
melanoma.
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Figure 3.4 Distribution and quantification of melanin and thymine-dimer positive
cells in neonatal UV-irradiated dorsal skin. Newborns (3.5 days old) were
exposed to 15 minutes of UV radiation and sacrificed 24 hours later for dorsal
skin removal. Melanin (A, B dark brown) and thimine-dimers (C, D green)
distribution in a dorsal skin cryosection of K5-Edn3 and non K5-Edn3 mice. (G,
H) overlapped pictures of thymine-dimer (C, D) staining and Hoechst (E, F) used
as countersating. (I) Quantification of thymine-dimer positive cells in the skin of
K5-End3 (n=3) and non K5-End3 (n=3). Bars represent means ± SD. Statistical
differences were calculated by one-way ANOVA (p<0.05, n=3 per genotype).
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IV. CONCLUSIONS, FUTURE DIRECTIONS AND IMPLICATIONS
4.1 Conclusions and Future Directions
Unlike many other cancers, melanoma affects people of all ages.
Melanoma incidence increases with age. Although pediatric cases are very rare,
melanoma is recognized as one of the most common cancers affecting a relative
young population. As in all cancers, melanoma initiation, progression and
metastasis is influenced by genetic and environmental factors as well as by
tumor-host interactions. Melanoma is notorious for its propensity to metastasize
and for its poor response to therapeutic regimens. In spite of all the efforts aimed
at elucidating the initiation and progression of this malignancy, it continues being
the most deadly form of skin cancer and its occurrence does not seem to be
decreasing anytime soon.
Mice are commonly used as disease models, however because of
structural differences between mice and human skin, in many of the attempts to
establish UV responsive mouse models, UV alone did not seem to be sufficient
to trigger melanoma development. In human skin, melanocytes are localized in
the basal layer of the epidermis. They make dendritic connections with
neighboring keratinocytes and transfer melanin to these cells, which provides
skin pigmentation and sunlight protection. In mouse skin, melanocytes
predominantly reside at the base of the hair follicles inside the dermis and are
only found in the epidermis in hairless areas, such as ears and tails (Fitch et al.,
2003; Hirobe, 1988). However, at specific periods, such as embryonic and
neonatal stages, melanocytes can be found in the epidermal-dermal junction
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(Hirobe, 1984). One possible explanation for wild type mice being highly resistant
to melanoma induction by UV irradiation is the protected location of melanocytes
inside the hair follicle deep into the mouse skin dermis rather than the epidermis
as in humans.
The K5-Edn3 double transgenic mice have a more “humanized” skin. The
production of excess Edn3 by epidermal keratinocytes leads to the accumulation
of large numbers of melanocytes in the skin, more specifically in the dermis and
epidermal-dermal junction, throughout their lifetime. As a consequence of the
presence

of

extra-follicular

melanocytes,

K5-Edn3

mice

display

a

hyperpigmented skin phenotype (Garcia et al., 2008). Because of the
resemblance with the human skin, we hypothesized that K5-Edn3 mice would
develop melanomagenesis upon UV radiation. I showed that, even though K5Edn3 mice do not develop spontaneous melanoma, a single neonatal UV
erythemal dose was capable of inducing melanomagenesis and its metastasis.
Unexpectedly, when K5-Edn3 mice were exposed to UV radiation neonatally as
well as during adulthood, a significant increase in melanoma penetrance was not
observed. One possible explanation for this surprising outcome is that the
majority of the lesions removed from K5-Edn3 mice exposed to both neonatal
and adult UV erythemal doses were very ulcerated. These lesions were very
excoriated with no residual epidermis, therefore only the dermal component
could be evaluated making it impossible to accurately diagnose them.
Interestingly, when adult mice (6 weeks of age) were exposed to a single
erythemal dose of UV radiation, they did not develop melanoma. This result
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underscored the importance of neonatal UV exposure in order for K5-Edn3 mice
to develop melanoma. Furthermore, it provided further support to the
epidemiological data indicating that early sun exposure is critical and sufficient
for melanomagenesis (Whiteman et al., 2001).
The reason for the neonatal sensitivity and lack of adult sensitivity to UV
radiation is not clear but it could be related to (1)- the fact that neonatal mice
have immune response distinct from adult mice, which can result in tolerance in
adults to antigens produced by UV exposure (Muller et al., 2008); and/or (2)- the
acquisition and retention of DNA damage by melanocyte progenitor cells found in
higher

amounts

in

post-natal

skin

than

in

adult

skin,

resulting

in

melanomagenesis later on in life (Wolnicka-Glubisz and Noonan, 2006).
Given that only K5-Edn3 mice develop melanoma upon neonatal UV
exposure, it is possible that Edn3 overexpression not only allows for the survival
of

melanocytes

in

the

extra-follicular

skin

but

also

affects

the

skin

microenvironment making it more susceptible to the development and
progression of melanoma. The latter is based on in vitro studies that showed
that, in melanoma cell lines, Edn3 alters the expression of cell adhesion proteins
and metalloproteinases that are associated with the disruption of normal tumorhost interactions and progression of cutaneous melanoma (Bagnato et al., 2004;
Rosano et al., 2004).
The K5-Edn3 mouse uses the tetracycline regulatory system to drive the
overexpression of Edn3 under the control of Keratin 5 promoter (Garcia et al.,
2008). Taking advantage of this system, it would be interesting to determine if
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overexpression of Edn3 in the skin of adult mice is a requirement for UV-induced
melanomagenesis and metastasis. The simple addition of doxycycline to the
drinking water of these mice, leads to the blockage of the Edn3 transgene. Since
overexpression of Edn3 in the skin is a requirement for extra-follicular
melanocyte persistence, K5-Edn3 transgenic mice would initially undergo the
same UV exposure regimen at 3.5 days of age, before the K5-Edn3 transgene
was turned off beginning at 21 days after birth. Doxycycline treatment would be
continued for 18 months and mice would be weekly checked for melanoma
appearance.
The Nucleotide Excision Repair (NER) pathway repairs photoproducts
induced by UV radiation; Xpa and Xpc proteins have important roles in this
pathway. Xpa deficiency and, in a higher magnitude Xpc deficiency, enhanced
melanoma penetrance and decreased melanoma latency in the neonatal K5Edn3 UV-induced mouse model. This result was expected and it is in accordance
with previously published data in humans and also in mouse models which links
NER pathway disruption to high indices of skin cancer, including melanoma
(Kraemer et al., 1987; Luo et al., 2013; Nakane et al., 1995; van Schanke et al.,
2006; Yamazaki et al., 2005; Yang et al., 2007).
Neonatal K5-Edn3 dorsal skin exposed to UV-radiation revealed a
decrease in thymine-dimer formation and a larger number of apoptotic cells in
comparison to neonatal non K5-Edn3 dorsal skin exposed to the same dose of
UV radiation. These observations can result from the effects caused by the
higher levels of Edn3 and/or larger amounts of melanin present in the skin of the
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K5-Edn3 mice. In order to isolate the contributions of Edn3 and melanin, K5Edn3 transgenic mice could be placed in an albino background, exposed to the
same regimen of UV radiation at 3.5 days of age, and monitored for a period of
18 months for melanoma development and metastasis. Wood et al. (2006)
reported on the possible involvement of melanin in phototoxic reactions
responsible for UV-dependent causation of melanoma in Xiphophorus (Wood et
al., 2006). A recent study showed that the presence of melanin is a requirement
for melanoma induction by UVA, but not UVB, in HGF/SC transgenic mice
(Noonan et al., 2012). Taking these results into account, I would expect that K5Edn3 on the albino background mice would not develop or would have a lower
incidence of melanomagenesis upon neonatal UV exposure.
Next generation sequencing of Braf, Kras, Hras and Nras PCR amplicons
did not reveal any mutations that would lead to constitutive activation of these
oncogenes in UV-induced K5-Edn3 melanoma lesions. In a recent published
paper, UV-induced p53 gene mutation was found to be the cause of
melanomagenesis acceleration in BRAFV600E mice (Viros et al., 2014). In light of
this, it would be of great interest to perform whole exome sequencing of K5-Edn3
melanoma lesions to find out which genes, if any, are the UV-targeted genes in
the K5-Edn3 model. This would help to further understand the molecular basis for
melanoma development in the UV-exposed K5-Edn3 mice.
Previously established neonatal, UV-induced melanoma mouse models
carried loss or gain of function mutations in the melanocytes and spontaneously
developed skin lesions that were enhanced by UV exposure. Most of the existing

123

models are based on disruption of tyrosine kinase receptor mediated signaling
pathways. The K5-Edn3 UV-induced melanoma mouse model is the first model
based on the over-activation of a G-coupled receptor. Additionally, the K5-Edn3
model has two very distinguishable features: (1)- melanocytes are not
transformed a priori and, (2)- the tumorigenic process depends exclusively on
neonatal UV radiation. Therefore, testing new chemical compounds, as well as
current and new melanoma therapies in this model would be of great relevance.
It will provide a very different platform for the evaluation of the efficacy of novel
drugs and, as such, be considered a new standard for pre-clinical studies.
4.2 Implications
Ultraviolet radiation is known to be the major environmental risk factor for
melanoma, but it is still unclear exactly how UV affects melanoma initiation,
progression and metastasis. The effects of UV radiation on organisms are very
broad making the solution to this puzzle particularly complex. Recently, with the
use of experimental animal models, some progress towards elucidating the
mechanisms at work in UV-induced melanomagenesis has been made.
The UV-induced K5-Edn3 melanoma mouse model developed in this
project establishes a new paradigm for the role of Edn3 in melanoma risk.
Further understanding of the precise cellular, biochemical and molecular
mechanisms employed by this pathway in the K5-Edn3 melanoma model will
substantially help in the advance of our understanding of the interactions
between UV radiation and skin carcinogenesis. In the near future, this model may

124

serve as a useful tool in the identification of new molecular targets for
intervention and also in the assessment of the efficacy of therapeutic agents.
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